{ "version": "2.2", "instance": { "bp31726520f.htm": { "nsprefix": "bdrx", "nsuri": "http://biodexapharma.com/20251231", "dts": { "schema": { "local": [ "bdrx-20251231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd", "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd", "https://xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd" ] }, "calculationLink": { "local": [ "bdrx-20251231_cal.xml" ] }, "definitionLink": { "local": [ "bdrx-20251231_def.xml" ], "remote": [ "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml" ] }, "labelLink": { "local": [ "bdrx-20251231_lab.xml" ] }, "presentationLink": { "local": [ "bdrx-20251231_pre.xml" ] }, "inline": { "local": [ "bp31726520f.htm" ] } }, "keyStandard": 217, "keyCustom": 229, "axisStandard": 20, "axisCustom": 2, "memberStandard": 32, "memberCustom": 113, "hidden": { "total": 671, "http://biodexapharma.com/20251231": 335, "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 332, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 662, "entityCount": 1, "segmentCount": 148, "elementCount": 720, "unitCount": 7, "baseTaxonomies": { "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 1353, "http://xbrl.sec.gov/dei/2024": 48 }, "report": { "R1": { "role": "http://biodexapharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R2": { "role": "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "longName": "00000002 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "ifrs-full:Revenue", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "ifrs-full:Revenue", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R3": { "role": "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "longName": "00000003 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NoncurrentAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R4": { "role": "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "longName": "00000004 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:ProfitLoss", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:AdjustmentsForDepreciationExpense", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R5": { "role": "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31_custom_ShareCapitalMember", "name": "ifrs-full:Equity", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_ShareCapitalMember", "name": "ifrs-full:Equity", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R6": { "role": "http://biodexapharma.com/role/AccountingPolicies", "longName": "999006 - Disclosure - Accounting policies", "shortName": "Accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "6", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R7": { "role": "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgements", "longName": "999007 - Disclosure - Critical accounting estimates and judgements", "shortName": "Critical accounting estimates and judgements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R8": { "role": "http://biodexapharma.com/role/Revenue", "longName": "999008 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfRevenueExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R9": { "role": "http://biodexapharma.com/role/LossFromOperations", "longName": "999009 - Disclosure - Loss from operations", "shortName": "Loss from operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R10": { "role": "http://biodexapharma.com/role/StaffCosts", "longName": "999010 - Disclosure - Staff costs", "shortName": "Staff costs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfStaffCostsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfStaffCostsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R11": { "role": "http://biodexapharma.com/role/FinanceIncomeAndExpense", "longName": "999011 - Disclosure - Finance income and expense", "shortName": "Finance income and expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R12": { "role": "http://biodexapharma.com/role/Taxation", "longName": "999012 - Disclosure - Taxation", "shortName": "Taxation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R13": { "role": "http://biodexapharma.com/role/LossPerShare", "longName": "999013 - Disclosure - Loss per share", "shortName": "Loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfEarningsPerSharesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfEarningsPerSharesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R14": { "role": "http://biodexapharma.com/role/PropertyPlantAndEquipment", "longName": "999014 - Disclosure - Property, plant and equipment", "shortName": "Property, plant and equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R15": { "role": "http://biodexapharma.com/role/Leases", "longName": "999015 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfLeaseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfLeaseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R16": { "role": "http://biodexapharma.com/role/IntangibleAssets", "longName": "999016 - Disclosure - Intangible assets", "shortName": "Intangible assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfIntangibleAssetExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfIntangibleAssetExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R17": { "role": "http://biodexapharma.com/role/Subsidiaries", "longName": "999017 - Disclosure - Subsidiaries", "shortName": "Subsidiaries", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R18": { "role": "http://biodexapharma.com/role/TradeAndOtherReceivables", "longName": "999018 - Disclosure - Trade and other receivables", "shortName": "Trade and other receivables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R19": { "role": "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotes", "longName": "999019 - Disclosure - Cash and cash equivalents and cash flow supporting notes", "shortName": "Cash and cash equivalents and cash flow supporting notes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R20": { "role": "http://biodexapharma.com/role/TradeAndOtherPayables", "longName": "999020 - Disclosure - Trade and other payables", "shortName": "Trade and other payables", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R21": { "role": "http://biodexapharma.com/role/DeferredConsideration", "longName": "999021 - Disclosure - Deferred consideration", "shortName": "Deferred consideration", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DeferredConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DeferredConsiderationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R22": { "role": "http://biodexapharma.com/role/Borrowings", "longName": "999022 - Disclosure - Borrowings", "shortName": "Borrowings", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R23": { "role": "http://biodexapharma.com/role/Provisions", "longName": "999023 - Disclosure - Provisions", "shortName": "Provisions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ProvisionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ProvisionsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R24": { "role": "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrent", "longName": "999024 - Disclosure - Derivative financial liability \u2013 current", "shortName": "Derivative financial liability \u2013 current", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R25": { "role": "http://biodexapharma.com/role/FinancialInstrumentsRiskManagement", "longName": "999025 - Disclosure - Financial instruments \u2013 risk management", "shortName": "Financial instruments \u2013 risk management", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R26": { "role": "http://biodexapharma.com/role/DeferredTax", "longName": "999026 - Disclosure - Deferred tax", "shortName": "Deferred tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDeferredTaxeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDeferredTaxeExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R27": { "role": "http://biodexapharma.com/role/ShareCapital", "longName": "999027 - Disclosure - Share capital", "shortName": "Share capital", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R28": { "role": "http://biodexapharma.com/role/Reserves", "longName": "999028 - Disclosure - Reserves", "shortName": "Reserves", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R29": { "role": "http://biodexapharma.com/role/RetirementBenefits", "longName": "999029 - Disclosure - Retirement benefits", "shortName": "Retirement benefits", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfRetirementBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfRetirementBenefitsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R30": { "role": "http://biodexapharma.com/role/Share-basedPayments", "longName": "999030 - Disclosure - Share-based payments", "shortName": "Share-based payments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R31": { "role": "http://biodexapharma.com/role/CapitalCommitments", "longName": "999031 - Disclosure - Capital commitments", "shortName": "Capital commitments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfCapitalCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfCapitalCommitmentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R32": { "role": "http://biodexapharma.com/role/RelatedPartyTransactions", "longName": "999032 - Disclosure - Related party transactions", "shortName": "Related party transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "32", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R33": { "role": "http://biodexapharma.com/role/ContingentLiabilities", "longName": "999033 - Disclosure - Contingent liabilities", "shortName": "Contingent liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "33", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R34": { "role": "http://biodexapharma.com/role/UltimateControllingParty", "longName": "999034 - Disclosure - Ultimate controlling party", "shortName": "Ultimate controlling party", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "34", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfUltimateControllingPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfUltimateControllingPartyExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R35": { "role": "http://biodexapharma.com/role/PostBalanceSheetEvents", "longName": "999035 - Disclosure - Post Balance Sheet Events", "shortName": "Post Balance Sheet Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "35", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosurePostBalanceSheetEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosurePostBalanceSheetEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R36": { "role": "http://biodexapharma.com/role/AccountingPoliciesPolicies", "longName": "999036 - Disclosure - Accounting policies (Policies)", "shortName": "Accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "36", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R37": { "role": "http://biodexapharma.com/role/AccountingPoliciesTables", "longName": "999037 - Disclosure - Accounting policies (Tables)", "shortName": "Accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfCompositionOfGroupExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R38": { "role": "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsTables", "longName": "999038 - Disclosure - Critical accounting estimates and judgements (Tables)", "shortName": "Critical accounting estimates and judgements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R39": { "role": "http://biodexapharma.com/role/RevenueTables", "longName": "999039 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R40": { "role": "http://biodexapharma.com/role/LossFromOperationsTables", "longName": "999040 - Disclosure - Loss from operations (Tables)", "shortName": "Loss from operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R41": { "role": "http://biodexapharma.com/role/StaffCostsTables", "longName": "999041 - Disclosure - Staff costs (Tables)", "shortName": "Staff costs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutStaffCostsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutStaffCostsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R42": { "role": "http://biodexapharma.com/role/FinanceIncomeAndExpenseTables", "longName": "999042 - Disclosure - Finance income and expense (Tables)", "shortName": "Finance income and expense (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R43": { "role": "http://biodexapharma.com/role/TaxationTables", "longName": "999043 - Disclosure - Taxation (Tables)", "shortName": "Taxation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R44": { "role": "http://biodexapharma.com/role/LossPerShareTables", "longName": "999044 - Disclosure - Loss per share (Tables)", "shortName": "Loss per share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "44", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R45": { "role": "http://biodexapharma.com/role/PropertyPlantAndEquipmentTables", "longName": "999045 - Disclosure - Property, plant and equipment (Tables)", "shortName": "Property, plant and equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "45", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R46": { "role": "http://biodexapharma.com/role/LeasesTables", "longName": "999046 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "46", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutMarketRentalRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutMarketRentalRatesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R47": { "role": "http://biodexapharma.com/role/IntangibleAssetsTables", "longName": "999047 - Disclosure - Intangible assets (Tables)", "shortName": "Intangible assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "47", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfIntangibleAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfIntangibleAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R48": { "role": "http://biodexapharma.com/role/SubsidiariesTables", "longName": "999048 - Disclosure - Subsidiaries (Tables)", "shortName": "Subsidiaries (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "48", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R49": { "role": "http://biodexapharma.com/role/TradeAndOtherReceivablesTables", "longName": "999049 - Disclosure - Trade and other receivables (Tables)", "shortName": "Trade and other receivables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "49", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfTradeAndOtherReceivableTableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfTradeAndOtherReceivableTableExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R50": { "role": "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesTables", "longName": "999050 - Disclosure - Cash and cash equivalents and cash flow supporting notes (Tables)", "shortName": "Cash and cash equivalents and cash flow supporting notes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "50", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R51": { "role": "http://biodexapharma.com/role/TradeAndOtherPayablesTables", "longName": "999051 - Disclosure - Trade and other payables (Tables)", "shortName": "Trade and other payables (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "51", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R52": { "role": "http://biodexapharma.com/role/DeferredConsiderationTables", "longName": "999052 - Disclosure - Deferred consideration (Tables)", "shortName": "Deferred consideration (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "52", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ScheduleOfDeferredConsiderationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ScheduleOfDeferredConsiderationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R53": { "role": "http://biodexapharma.com/role/BorrowingsTables", "longName": "999053 - Disclosure - Borrowings (Tables)", "shortName": "Borrowings (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "53", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationBorrowingsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R54": { "role": "http://biodexapharma.com/role/ProvisionsTables", "longName": "999054 - Disclosure - Provisions (Tables)", "shortName": "Provisions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "54", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationProvisionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:ProvisionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfDetailedInformationProvisionExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:ProvisionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R55": { "role": "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentTables", "longName": "999055 - Disclosure - Derivative financial liability \u2013 current (Tables)", "shortName": "Derivative financial liability \u2013 current (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "55", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R56": { "role": "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables", "longName": "999056 - Disclosure - Financial instruments \u2013 risk management (Tables)", "shortName": "Financial instruments \u2013 risk management (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "56", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R57": { "role": "http://biodexapharma.com/role/DeferredTaxTables", "longName": "999057 - Disclosure - Deferred tax (Tables)", "shortName": "Deferred tax (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "57", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R58": { "role": "http://biodexapharma.com/role/ShareCapitalTables", "longName": "999058 - Disclosure - Share capital (Tables)", "shortName": "Share capital (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "58", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfIssuedCapital1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfIssuedCapital1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R59": { "role": "http://biodexapharma.com/role/ReservesTables", "longName": "999059 - Disclosure - Reserves (Tables)", "shortName": "Reserves (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "59", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfReservesAndOtherEquityInterest1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfReservesAndOtherEquityInterest1Explanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R60": { "role": "http://biodexapharma.com/role/Share-basedPaymentsTables", "longName": "999060 - Disclosure - Share-based payments (Tables)", "shortName": "Share-based payments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "60", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R61": { "role": "http://biodexapharma.com/role/AccountingPoliciesDetails", "longName": "999061 - Disclosure - Accounting policies (Details)", "shortName": "Accounting policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_BiodexaPharmaceuticalsplcMember", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfCompositionOfGroupExplanatory", "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_BiodexaPharmaceuticalsplcMember", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfCompositionOfGroupExplanatory", "bdrx:DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R62": { "role": "http://biodexapharma.com/role/AccountingPoliciesDetails1", "longName": "999062 - Disclosure - Accounting policies (Details 1)", "shortName": "Accounting policies (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:Prepayments", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfTradeAndOtherReceivableTableExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_FAPProjectsMember", "name": "ifrs-full:Prepayments", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfFapProjectTableTextBlock", "bdrx:AccountingForRrapaAndCpritGrantPolicyTextBlock", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R63": { "role": "http://biodexapharma.com/role/AccountingPoliciesDetails2", "longName": "999063 - Disclosure - Accounting policies (Details 2)", "shortName": "Accounting policies (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_ifrs-full_GoodwillMember", "name": "ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_ifrs-full_GoodwillMember", "name": "ifrs-full:DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R64": { "role": "http://biodexapharma.com/role/AccountingPoliciesDetails3", "longName": "999064 - Disclosure - Accounting policies (Details 3)", "shortName": "Accounting policies (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_ifrs-full_FixturesAndFittingsMember", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDepreciationRatesOfPropertyPlantAndEquipmentTableExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_ifrs-full_FixturesAndFittingsMember", "name": "ifrs-full:DescriptionOfUsefulLifePropertyPlantAndEquipment", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDepreciationRatesOfPropertyPlantAndEquipmentTableExplanatory", "ifrs-full:DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R65": { "role": "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "longName": "999065 - Disclosure - Accounting policies (Details Narrative)", "shortName": "Accounting policies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LossFromOperations", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DescriptionOfAccountingPolicyForGoingConcernExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LossFromOperations", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DescriptionOfAccountingPolicyForGoingConcernExplanatory", "ifrs-full:DisclosureOfChangesInAccountingPoliciesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R66": { "role": "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "longName": "999066 - Disclosure - Critical accounting estimates and judgements (Details)", "shortName": "Critical accounting estimates and judgements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_MTX228TolimidoneAcquiredIPRDMember", "name": "bdrx:PercentageChangeInFairValue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_MTX228TolimidoneAcquiredIPRDMember", "name": "bdrx:PercentageChangeInFairValue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfPlanAssetsExplanatory", "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R67": { "role": "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetailsNarrative", "longName": "999067 - Disclosure - Critical accounting estimates and judgements (Details Narrative)", "shortName": "Critical accounting estimates and judgements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:CarryingValueOfIntangiblesNotYetReadyForUse", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:CarryingValueOfIntangiblesNotYetReadyForUse", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfCriticalAccountingEstimatesAndJudgements", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R68": { "role": "http://biodexapharma.com/role/RevenueDetails", "longName": "999068 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "bdrx:SalesRevenue", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "bdrx:SalesRevenue", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfGeographicalAreasExplanatory", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R69": { "role": "http://biodexapharma.com/role/RevenueDetails1", "longName": "999069 - Disclosure - Revenue (Details 1)", "shortName": "Revenue (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "ifrs-full:ContractAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:PerformanceObligationsTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "ifrs-full:ContractLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:PerformanceObligationsTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R70": { "role": "http://biodexapharma.com/role/RevenueDetails2", "longName": "999070 - Disclosure - Revenue (Details 2)", "shortName": "Revenue (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomersAMember", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfCommercialSegmentsTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31_custom_CustomersAMember", "name": "ifrs-full:PercentageOfEntitysRevenue", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfCommercialSegmentsTableTextBlock", "ifrs-full:DisclosureOfRevenueExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R71": { "role": "http://biodexapharma.com/role/LossFromOperationsDetails", "longName": "999071 - Disclosure - Loss from operations (Details)", "shortName": "Loss from operations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "bdrx:ImpairmentOfFinancialAsset", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-01-012023-12-31", "name": "bdrx:ImpairmentOfFinancialAsset", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory", "ifrs-full:DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R72": { "role": "http://biodexapharma.com/role/StaffCostsDetails", "longName": "999072 - Disclosure - Staff costs (Details)", "shortName": "Staff costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:WagesAndSalaries", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutStaffCostsExplanatory", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:WagesAndSalaries", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutStaffCostsExplanatory", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R73": { "role": "http://biodexapharma.com/role/StaffCostsDetails1", "longName": "999073 - Disclosure - Staff costs (Details 1)", "shortName": "Staff costs (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfAverageNumberOfStaffEmployeeExplanatory", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:AverageNumberOfEmployees", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfAverageNumberOfStaffEmployeeExplanatory", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R74": { "role": "http://biodexapharma.com/role/StaffCostsDetails2", "longName": "999074 - Disclosure - Staff costs (Details 2)", "shortName": "Staff costs (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ShortTermEmployeeBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleOfManagementPersonalCompensationTableTextBlock", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-12-31", "name": "bdrx:TerminationBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleOfManagementPersonalCompensationTableTextBlock", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R75": { "role": "http://biodexapharma.com/role/StaffCostsDetails3", "longName": "999075 - Disclosure - Staff costs (Details 3)", "shortName": "Staff costs (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ShortTermEmployeeBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleOfManagementPersonalCompensationTableTextBlock", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_srt_DirectorMember", "name": "bdrx:ShortTermEmployeeBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleofEmolumentsDisclosedTableTextBlock", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R76": { "role": "http://biodexapharma.com/role/StaffCostsDetailsNarrative", "longName": "999076 - Disclosure - Staff costs (Details Narrative)", "shortName": "Staff costs (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfInformationAboutKeyManagementPersonnel", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DisclosureOfInformationAboutKeyManagementPersonnel", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DisclosureOfStaffCostsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R77": { "role": "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails", "longName": "999077 - Disclosure - Finance income and expense (Details)", "shortName": "Finance income and expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:InterestIncomeOnDeposits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:InterestIncomeOnDeposits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R78": { "role": "http://biodexapharma.com/role/TaxationDetails", "longName": "999078 - Disclosure - Taxation (Details)", "shortName": "Taxation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:CurrentTaxCreditedToIncomeStatement", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:CurrentTaxCreditedToIncomeStatement", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R79": { "role": "http://biodexapharma.com/role/TaxationDetails1", "longName": "999079 - Disclosure - Taxation (Details 1)", "shortName": "Taxation (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LossBeforeTax", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutDifferenceBetweenActualTaxChargeAndStandardTateOfCorporationTaxExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LossBeforeTax", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutDifferenceBetweenActualTaxChargeAndStandardTateOfCorporationTaxExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R80": { "role": "http://biodexapharma.com/role/LossPerShareDetails", "longName": "999080 - Disclosure - Loss per share (Details)", "shortName": "Loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "80", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory", "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:ProfitLossFromContinuingOperations", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory", "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R81": { "role": "http://biodexapharma.com/role/LossPerShareDetailsNarrative", "longName": "999081 - Disclosure - Loss per share (Details Narrative)", "shortName": "Loss per share (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "81", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DescriptionOStockholdersEquityNoteStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:DescriptionOStockholdersEquityNoteStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DisclosureOfEarningsPerSharesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R82": { "role": "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "longName": "999082 - Disclosure - Property, plant and equipment (Details)", "shortName": "Property, plant and equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "82", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_GrossGrossGrossCarryingAmountMember", "name": "ifrs-full:PropertyPlantAndEquipment", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R83": { "role": "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative", "longName": "999083 - Disclosure - Property, plant and equipment (Details Narrative)", "shortName": "Property, plant and equipment (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "83", "firstAnchor": { "contextRef": "AsOf2025-12-31_ifrs-full_LeaseholdImprovementsMember", "name": "ifrs-full:RightofuseAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_ifrs-full_LeaseholdImprovementsMember", "name": "ifrs-full:RightofuseAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfPropertyPlantAndEquipmentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R84": { "role": "http://biodexapharma.com/role/LeasesDetails", "longName": "999084 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "84", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:InterestExpenseOnLeaseLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_ifrs-full_LandAndBuildingsMember", "name": "ifrs-full:LeaseLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutMarketRentalRatesExplanatory", "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R85": { "role": "http://biodexapharma.com/role/LeasesDetails1", "longName": "999085 - Disclosure - Leases (Details 1)", "shortName": "Leases (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "85", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LowValueLeasesExpensed", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfLowValueLeasesExpensed", "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LowValueLeasesExpensed", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfLowValueLeasesExpensed", "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R86": { "role": "http://biodexapharma.com/role/LeasesDetailsNarrative", "longName": "999086 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "86", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:TotalCashOutflowForLeases", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:TotalCashOutflowForLeases", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfLeaseExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R87": { "role": "http://biodexapharma.com/role/IntangibleAssetsDetails", "longName": "999087 - Disclosure - Intangible assets (Details)", "shortName": "Intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "87", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_custom_GrossGrossGrossCarryingAmountMember", "name": "ifrs-full:IntangibleAssetsAndGoodwill", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "bdrx:DisclosureOfIntangibleAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R88": { "role": "http://biodexapharma.com/role/IntangibleAssetsDetails1", "longName": "999088 - Disclosure - Intangible assets (Details 1)", "shortName": "Intangible assets (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "88", "firstAnchor": { "contextRef": "AsOf2025-12-31_custom_MTX228TolimidoneAcquiredIPRDMember", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOffCondensedFinancialStatementsTableTextBlock", "bdrx:DisclosureOfIntangibleAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_MTX228TolimidoneAcquiredIPRDMember", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOffCondensedFinancialStatementsTableTextBlock", "bdrx:DisclosureOfIntangibleAssetExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R89": { "role": "http://biodexapharma.com/role/SubsidiariesDetails", "longName": "999089 - Disclosure - Subsidiaries (Details)", "shortName": "Subsidiaries (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "89", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_BiodexaAustraliaPTYLimited1Member", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "bdrx:DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_BiodexaAustraliaPTYLimited1Member", "name": "ifrs-full:NameOfSubsidiary", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "span", "td", "tr", "table", "bdrx:DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R90": { "role": "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails", "longName": "999090 - Disclosure - Trade and other receivables (Details)", "shortName": "Trade and other receivables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "90", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:TradeReceivables", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfTradeAndOtherReceivableTableExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:TradeReceivables", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfTradeAndOtherReceivableTableExplanatory", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R91": { "role": "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails", "longName": "999091 - Disclosure - Cash and cash equivalents and cash flow supporting notes (Details)", "shortName": "Cash and cash equivalents and cash flow supporting notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "91", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": null }, "R92": { "role": "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails1", "longName": "999092 - Disclosure - Cash and cash equivalents and cash flow supporting notes (Details 1)", "shortName": "Cash and cash equivalents and cash flow supporting notes (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "92", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:FundsRaisedOnPublicOffering", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutShareIssuesNetOfCostsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:FundsRaisedOnPublicOffering", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutShareIssuesNetOfCostsExplanatory", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R93": { "role": "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2", "longName": "999093 - Disclosure - Cash and cash equivalents and cash flow supporting notes (Details 2)", "shortName": "Cash and cash equivalents and cash flow supporting notes (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "93", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory1", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "ifrs-full:LiabilitiesArisingFromFinancingActivities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory1", "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R94": { "role": "http://biodexapharma.com/role/TradeAndOtherPayablesDetails", "longName": "999094 - Disclosure - Trade and other payables (Details)", "shortName": "Trade and other payables (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "94", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:AccrualsClassifiedAsCurrent", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R95": { "role": "http://biodexapharma.com/role/DeferredConsiderationDetails", "longName": "999095 - Disclosure - Deferred consideration (Details)", "shortName": "Deferred consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "95", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:DeferredConsiderationOpeningProvision", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleOfDeferredConsiderationTableTextBlock", "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:DeferredConsiderationOpeningProvision", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "bdrx:ScheduleOfDeferredConsiderationTableTextBlock", "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R96": { "role": "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative", "longName": "999096 - Disclosure - Deferred consideration (Details Narrative)", "shortName": "Deferred consideration (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "96", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LiabilityIncreaseAndDecreaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:LiabilityIncreaseAndDecreaseDescription", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "bdrx:DeferredConsiderationTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R97": { "role": "http://biodexapharma.com/role/BorrowingsDetails", "longName": "999097 - Disclosure - Borrowings (Details)", "shortName": "Borrowings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "97", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationBorrowingsExplanatory", "ifrs-full:DisclosureOfBorrowingsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R98": { "role": "http://biodexapharma.com/role/ProvisionsDetails", "longName": "999098 - Disclosure - Provisions (Details)", "shortName": "Provisions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "98", "firstAnchor": { "contextRef": "AsOf2022-12-31", "name": "bdrx:Provision", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationProvisionExplanatory", "bdrx:ProvisionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31", "name": "bdrx:Provision", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfDetailedInformationProvisionExplanatory", "bdrx:ProvisionsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R99": { "role": "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails", "longName": "999099 - Disclosure - Derivative financial liability - current (Details)", "shortName": "Derivative financial liability - current (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "99", "firstAnchor": { "contextRef": "AsOf2024-12-31", "name": "ifrs-full:CurrentDerivativeFinancialLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:GainLossOfEquitySettledDerivativeFinancialLiability", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:MaturityAnalysisForDerivativeFinancialLiabilities", "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R100": { "role": "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1", "longName": "999100 - Disclosure - Derivative financial liability - current (Details 1)", "shortName": "Derivative financial liability - current (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "100", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_WarrantOneMember", "name": "bdrx:NumberOfSharesOutstandingGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_WarrantOneMember", "name": "bdrx:NumberOfSharesOutstandingGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R101": { "role": "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative", "longName": "999101 - Disclosure - Derivative financial liability \u2013 current (Details Narrative)", "shortName": "Derivative financial liability \u2013 current (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "101", "firstAnchor": { "contextRef": "From2025-12-012025-12-31_custom_SeriesLADSwarrantsMember", "name": "bdrx:NumberOfWarrantsIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-12-012025-12-31_custom_SeriesLADSwarrantsMember", "name": "bdrx:NumberOfWarrantsIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "bdrx:DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R102": { "role": "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails", "longName": "999102 - Disclosure - Financial instruments - risk management (Details)", "shortName": "Financial instruments - risk management (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "102", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CurrentTradeReceivables", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R103": { "role": "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1", "longName": "999103 - Disclosure - Financial instruments - risk management (Details 1)", "shortName": "Financial instruments - risk management (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "103", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:CurrentDerivativeFinancialLiabilities1", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfConsolidatedFinancialAssetsAndLiabilitiesValuedAtFairValueExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:CurrentDerivativeFinancialLiabilities1", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfConsolidatedFinancialAssetsAndLiabilitiesValuedAtFairValueExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R104": { "role": "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "longName": "999104 - Disclosure - Financial instruments - risk management (Details 2)", "shortName": "Financial instruments - risk management (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "104", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_custom_ForeignExchangeRiskMember_currency_GBP", "name": "ifrs-full:CashAndCashEquivalents", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfForeignExchangeRiskExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R105": { "role": "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3", "longName": "999105 - Disclosure - Financial instruments - risk management (Details 3)", "shortName": "Financial instruments - risk management (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "105", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_ForeignCurrencySensitivityAnalysisMember_currency_USD", "name": "ifrs-full:ProfitLossBeforeTax", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfForeignCurrencyExchangeRatesExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R106": { "role": "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4", "longName": "999106 - Disclosure - Financial instruments - risk management (Details 4)", "shortName": "Financial instruments - risk management (Details 4)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "106", "firstAnchor": { "contextRef": "AsOf2025-12-31_ifrs-full_LiquidityRiskMember_ifrs-full_NotLaterThanThreeMonthsMember", "name": "ifrs-full:FinancialLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfMaturitiesOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_ifrs-full_LiquidityRiskMember_ifrs-full_NotLaterThanThreeMonthsMember", "name": "ifrs-full:FinancialLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfMaturitiesOfFinancialInstrumentsExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R107": { "role": "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative", "longName": "999107 - Disclosure - Financial instruments \u2013 risk management (Details Narrative)", "shortName": "Financial instruments \u2013 risk management (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "107", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ProceedsFromEquityLineOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:ProceedsFromEquityLineOfCredit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R108": { "role": "http://biodexapharma.com/role/DeferredTaxDetails", "longName": "999108 - Disclosure - Deferred tax (Details)", "shortName": "Deferred tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "108", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NetDeferredTaxLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NetDeferredTaxLiabilities", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R109": { "role": "http://biodexapharma.com/role/DeferredTaxDetailsNarrative", "longName": "999109 - Disclosure - Deferred tax (Details Narrative)", "shortName": "Deferred tax (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "109", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NetDeferredTaxAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NetDeferredTaxAssets", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfDeferredTaxeExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R110": { "role": "http://biodexapharma.com/role/ShareCapitalDetails", "longName": "999110 - Disclosure - Share capital (Details)", "shortName": "Share capital (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "110", "firstAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:ValueOfShares", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfIssuedCapital1Explanatory", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "bdrx:ValueOfShares", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfIssuedCapital1Explanatory", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R111": { "role": "http://biodexapharma.com/role/ShareCapitalDetails1", "longName": "999111 - Disclosure - Share capital (Details 1)", "shortName": "Share capital (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "111", "firstAnchor": { "contextRef": "AsOf2024-12-31_custom_PreFundedWarrantsMember", "name": "bdrx:NumberOfShareIssuedForConsideration", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfWarrantReserveRecognizedTableTextBlock", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-12-31_custom_PreFundedWarrantsMember", "name": "bdrx:NumberOfShareIssuedForConsideration", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfWarrantReserveRecognizedTableTextBlock", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R112": { "role": "http://biodexapharma.com/role/ShareCapitalDetails2", "longName": "999112 - Disclosure - Share capital (Details 2)", "shortName": "Share capital (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "112", "firstAnchor": { "contextRef": "AsOf2024-12-31_ifrs-full_OrdinarySharesMember", "name": "bdrx:NumberOfShareIssuedForConsideration", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfOrdinaryAndDeferredShares", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-31_ifrs-full_OrdinarySharesMember", "name": "bdrx:NumberOfShareIssuedForConsideration", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:DisclosureOfOrdinaryAndDeferredShares", "ifrs-full:DisclosureOfIssuedCapitalExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R113": { "role": "http://biodexapharma.com/role/ReservesDetails", "longName": "999113 - Disclosure - Reserves (Details)", "shortName": "Reserves (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "113", "firstAnchor": { "contextRef": "From2025-01-012025-12-31_custom_ShareCapitalMember", "name": "ifrs-full:DescriptionOfNatureAndPurposeOfReservesWithinEquity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfReservesAndOtherEquityInterest1Explanatory", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-012025-12-31_custom_ShareCapitalMember", "name": "ifrs-full:DescriptionOfNatureAndPurposeOfReservesWithinEquity", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "bdrx:DisclosureOfReservesAndOtherEquityInterest1Explanatory", "ifrs-full:DisclosureOfReservesAndOtherEquityInterestExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R114": { "role": "http://biodexapharma.com/role/RetirementBenefitsDetailsNarrative", "longName": "999114 - Disclosure - Retirement benefits (Details Narrative)", "shortName": "Retirement benefits (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "114", "firstAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:RetirementBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfRetirementBenefitsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2025-01-01to2025-12-31", "name": "bdrx:RetirementBenefits", "unitRef": "GBP", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "bdrx:DisclosureOfRetirementBenefitsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } }, "R115": { "role": "http://biodexapharma.com/role/Share-basedPaymentsDetails", "longName": "999115 - Disclosure - Share-based payments (Details)", "shortName": "Share-based payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "115", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31", "name": "ifrs-full:NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R116": { "role": "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "longName": "999116 - Disclosure - Share-based payments (Details 1)", "shortName": "Share-based payments (Details 1)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "116", "firstAnchor": { "contextRef": "From2024-07-012024-07-31", "name": "ifrs-full:NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-07-012024-07-31", "name": "bdrx:ExercisePriceOfOptionsIssuedInYear", "unitRef": "GBPPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R117": { "role": "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "longName": "999117 - Disclosure - Share-based payments (Details 2)", "shortName": "Share-based payments (Details 2)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "117", "firstAnchor": { "contextRef": "AsOf2023-12-31", "name": "ifrs-full:NumberOfOutstandingShareOptions", "unitRef": "N", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2025-12-31_ifrs-full_WarrantsMember", "name": "bdrx:WeightedAverageExercisePriceOfShareOptionsOutstanding", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfWarrantsAccountedForShareBasedPaymentsTableTextBlock", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R118": { "role": "http://biodexapharma.com/role/Share-basedPaymentsDetails3", "longName": "999118 - Disclosure - Share-based payments (Details 3)", "shortName": "Share-based payments (Details 3)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "118", "firstAnchor": { "contextRef": "From2024-07-012024-07-31", "name": "ifrs-full:DescriptionOfOptionPricingModelShareOptionsGranted", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2025-12-012025-12-31_ifrs-full_WarrantsMember", "name": "bdrx:NumberOfAdsWarrantsGranted", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "bdrx:ScheduleOfFairValueOfWarrantsGrantedTableTextBlock", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "unique": true } }, "R119": { "role": "http://biodexapharma.com/role/ContingentLiabilitiesDetailsNarrative", "longName": "999119 - Disclosure - Contingent liabilities (Details Narrative)", "shortName": "Contingent liabilities (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "119", "firstAnchor": { "contextRef": "AsOf2022-12-18", "name": "bdrx:AggregateConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2022-12-18", "name": "bdrx:AggregateConsideration", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "span", "p", "ifrs-full:DisclosureOfContingentLiabilitiesExplanatory", "body", "html" ], "reportCount": 1, "baseRef": "bp31726520f.htm", "first": true, "unique": true } } }, "tag": { "bdrx_ADeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ADeferredSharesMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "\u0091A\u0092 deferred shares [member]" } } }, "auth_ref": [] }, "bdrx_AccountingForRrapaAndCpritGrantPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AccountingForRrapaAndCpritGrantPolicyTextBlock", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting for rRapa and CPRIT grant" } } }, "auth_ref": [] }, "ifrs-full_Accruals": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Accruals", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Accruals", "label": "Accruals [Default Label]" } }, "en": { "role": { "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_AccrualsClassifiedAsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccrualsClassifiedAsCurrent", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_CurrentFinancialLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Accruals" } }, "en": { "role": { "documentation": "The amount of accruals classified as current. [Refer: Accruals]" } } }, "auth_ref": [ "r247" ] }, "bdrx_AccruedRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AccruedRevenue", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en-us": { "role": { "label": "Accrued revenue" } } }, "auth_ref": [] }, "bdrx_AccumulatedAmortisationAndImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AccumulatedAmortisationAndImpairment", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at end", "label": "AccumulatedAmortisationAndImpairment" } } }, "auth_ref": [] }, "bdrx_AccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AccumulatedDeficit", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated deficit", "label": "AccumulatedDeficit" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } } }, "auth_ref": [ "r42", "r49", "r72", "r78", "r81" ] }, "bdrx_AccumulatedDepreciationAndAmortisation": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AccumulatedDepreciationAndAmortisation", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "label": "AccumulatedDepreciationAndAmortisation" } } }, "auth_ref": [] }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AccumulatedDepreciationAndAmortisationMember", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]" } }, "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } } }, "auth_ref": [ "r49", "r252", "r256", "r260", "r262" ] }, "ifrs-full_AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdditionsOtherThanThroughBusinessCombinationsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Additions" } }, "en": { "role": { "documentation": "The amount of additions to property, plant and equipment other than those acquired through business combinations. [Refer: Total for all business combinations [member]; Property, plant and equipment]" } } }, "auth_ref": [ "r43" ] }, "dei_AddressTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AddressTypeDomain", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "auth_ref": [] }, "bdrx_AdjustmentInRespectOfPriorYear": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AdjustmentInRespectOfPriorYear", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "label": "Adjustment in respect of prior year" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForAmortisationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForAmortisationExpense", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortisation of intangible fixed assets" } }, "en": { "role": { "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]" } } }, "auth_ref": [ "r266" ] }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Decrease/(Increase) in trade and other receivables" } }, "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_AdjustmentsForDepreciationExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForDepreciationExpense", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation of property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r266" ] }, "ifrs-full_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loss on disposal of \u00a0property, plant and equipment", "label": "Adjustments for gain (loss) on disposals, property, plant and equipment" } }, "en": { "role": { "documentation": "Adjustments for gain (loss) on disposals of property, plant and equipment to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Property, plant and equipment; Disposals, property, plant and equipment]" } } }, "auth_ref": [ "r266" ] }, "bdrx_AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AdjustmentsForGainLossOnDisposalsPropertyPlantAndEquipment1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Loss on disposal of property, plant and equipment" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncomeTaxExpense", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Taxation" } }, "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r88" ] }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Decrease)/Increase in trade and other payables" } }, "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r264" ] }, "ifrs-full_AdjustmentsForProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForProvisions", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Decrease)/Increase in provisions" } }, "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } } }, "auth_ref": [ "r265" ] }, "bdrx_AdjustmentsForProvisions1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AdjustmentsForProvisions1", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Provision recognised in the year" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForReconcileProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLoss", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash flows from operating activities before changes in working capital", "label": "Adjustments to reconcile profit (loss)" } }, "en": { "role": { "documentation": "Adjustments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r84" ] }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForReconcileProfitLossAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments for:" } } }, "auth_ref": [] }, "ifrs-full_AdjustmentsForSharebasedPayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForSharebasedPayments", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/StaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based payment charge", "verboseLabel": "Equity settled share-based payment \u2013 employee schemes" } }, "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r265" ] }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange (gain)/loss" } }, "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r205", "r265" ] }, "bdrx_AdjustmentsToBroughtForwardValues": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AdjustmentsToBroughtForwardValues", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "negatedLabel": "Adjustment in respect of prior period", "label": "AdjustmentsToBroughtForwardValues" } } }, "auth_ref": [] }, "bdrx_AdministrativeCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AdministrativeCostsMember", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Administrative costs [member]" } } }, "auth_ref": [] }, "ifrs-full_AdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AdministrativeExpense", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Administrative costs", "label": "Administrative expenses" } }, "en": { "role": { "documentation": "The amount of expenses that the entity classifies as being administrative." } } }, "auth_ref": [ "r33", "r56", "r183" ] }, "bdrx_AggregateConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AggregateConsideration", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Aggregate consideration" } } }, "auth_ref": [] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ifrs-full_AmortisationIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AmortisationIntangibleAssetsOtherThanGoodwill", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation charge for the year" } }, "en": { "role": { "documentation": "The amount of amortisation of intangible assets other than goodwill. [Refer: Depreciation and amortisation expense; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r73" ] }, "bdrx_AmortisationOfIntangibleAssetsSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AmortisationOfIntangibleAssetsSoftware", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Amortisation of intangible assets - software" } } }, "auth_ref": [] }, "bdrx_AmountsIncludedInContractLiabilitiesThatWasRecognisedAsRevenueDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AmountsIncludedInContractLiabilitiesThatWasRecognisedAsRevenueDuringPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Amounts included in contract liabilities that was recognised as revenue during the period" } } }, "auth_ref": [] }, "bdrx_AmountsPaidOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "AmountsPaidOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amounts paid on lease liabilities" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r234" ] }, "ifrs-full_Assets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Assets", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]" } }, "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r112", "r113", "r115", "r171", "r174" ] }, "ifrs-full_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AssetsAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r234" ] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r231", "r233", "r234" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r231", "r233", "r234" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r231", "r233", "r234" ] }, "ifrs-full_AverageNumberOfEmployees": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "AverageNumberOfEmployees", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails1" ], "lang": { "en-us": { "role": { "label": "Average number of staff employee" } }, "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } } }, "auth_ref": [ "r243" ] }, "bdrx_BDeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BDeferredSharesMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "\u0091B\u0092 deferred shares [member]" } } }, "auth_ref": [] }, "bdrx_BasicAndDilutedEarningsLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BasicAndDilutedEarningsLossPerShareAbstract", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic and diluted loss per share:" } } }, "auth_ref": [] }, "ifrs-full_BasicEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BasicEarningsLossPerShare", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Basic loss perordinary share", "verboseLabel": "Basic loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } } }, "auth_ref": [ "r64", "r65" ] }, "bdrx_BelgiumMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BelgiumMember", "presentation": [ "http://biodexapharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Belgium [Member]" } } }, "auth_ref": [] }, "bdrx_BiodexaAustraliaPTYLimited1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaAustraliaPTYLimited1Member", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Australia PTY Limited 1 [member]" } } }, "auth_ref": [] }, "bdrx_BiodexaAustraliaPTYLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaAustraliaPTYLimitedMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Australia PTY Limited [member]" } } }, "auth_ref": [] }, "bdrx_BiodexaIrelandLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaIrelandLimitedMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Ireland Limited [Member]" } } }, "auth_ref": [] }, "bdrx_BiodexaLimited1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaLimited1Member", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Limited 1 [Member]" } } }, "auth_ref": [] }, "bdrx_BiodexaLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaLimitedMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Limited [Member]" } } }, "auth_ref": [] }, "bdrx_BiodexaPharmaceuticalsWalesLimitedFormerlyMidatechPharmaWaleLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaPharmaceuticalsWalesLimitedFormerlyMidatechPharmaWaleLimitedMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Pharmaceuticals (Wales) Limited [member]" } } }, "auth_ref": [] }, "bdrx_BiodexaPharmaceuticalsWalesLimitedFormerlyMidatechPharmaWalesLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaPharmaceuticalsWalesLimitedFormerlyMidatechPharmaWalesLimitedMember", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Pharmaceuticals Wales Limited Formerly Midatech Pharma Wales Limited [Member]" } } }, "auth_ref": [] }, "bdrx_BiodexaPharmaceuticalsplcMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaPharmaceuticalsplcMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa Pharmaceuticals PLC [member]" } } }, "auth_ref": [] }, "bdrx_BiodexaUSIncMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BiodexaUSIncMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Biodexa US, Inc [Member]" } } }, "auth_ref": [] }, "ifrs-full_BiologicalAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BiologicalAssetsAxis", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Biological assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r261" ] }, "ifrs-full_BiologicalAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "BiologicalAssetsDomain", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for living animals or plants. It also represents the standard value for the 'Biological assets' axis if no other member is used." } } }, "auth_ref": [ "r261" ] }, "bdrx_BlackScholesOptionPricingModelFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelFiveMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model five [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelFourMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model four [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model [member]", "documentation": "The information of black scholes option pricing model." } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelOneMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model one [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelSevenMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model seven [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelSixMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model six [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelThreeMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model three [member]" } } }, "auth_ref": [] }, "bdrx_BlackScholesOptionPricingModelTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "BlackScholesOptionPricingModelTwoMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Black-Scholes option pricing model two [member]" } } }, "auth_ref": [] }, "ifrs-full_Borrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Borrowings", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "verboseLabel": "Borrowings", "label": "Borrowings [Default Label]" } }, "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } } }, "auth_ref": [ "r245" ] }, "bdrx_Borrowings1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Borrowings1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Borrowings", "documentation": "The amount of outstanding funds of the entity that is obligated to repay.", "label": "Borrowings1" } } }, "auth_ref": [] }, "dei_BusinessContactMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "BusinessContactMember", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Business Contact [Member]", "documentation": "Business contact for the entity" } } }, "auth_ref": [ "r233", "r234" ] }, "bdrx_CDeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CDeferredSharesMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "\u0091C\u0092 deferred shares [member]" } } }, "auth_ref": [] }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r42", "r46", "r72", "r74", "r77", "r78", "r79", "r80", "r81", "r150", "r159", "r160" ] }, "ifrs-full_CarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CarryingAmountMember", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } } }, "auth_ref": [ "r46", "r74", "r77", "r79", "r80", "r150", "r159", "r160" ] }, "bdrx_CarryingValueOfIntangiblesNotYetReadyForUse": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CarryingValueOfIntangiblesNotYetReadyForUse", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Carrying value of intangibles not yet ready for use" } } }, "auth_ref": [] }, "ifrs-full_Cash": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Cash", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } } }, "auth_ref": [ "r267" ] }, "ifrs-full_CashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails", "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "periodStartLabel": "Cash and cash equivalents at beginning of year", "periodEndLabel": "Cash and cash equivalents at end of year", "verboseLabel": "Cash at bank available on demand" } }, "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } } }, "auth_ref": [ "r10", "r91", "r109" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash generated from financing activities", "label": "Cash flows from (used in) financing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations." } } }, "auth_ref": [ "r82", "r92" ] }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Financing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in)/generated from investing activities", "label": "Cash flows from (used in) investing activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations." } } }, "auth_ref": [ "r82", "r92" ] }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Investing activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivities", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Cash flows from (used in) operating activities" } }, "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]" } } }, "auth_ref": [ "r82", "r92" ] }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "auth_ref": [] }, "ifrs-full_CashFlowsFromUsedInOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CashFlowsFromUsedInOperations", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Cash used in operations", "label": "Cash flows from (used in) operations" } }, "en": { "role": { "documentation": "The cash from (used in) the entity's operations." } } }, "auth_ref": [ "r202", "r205" ] }, "bdrx_CashReceivedInAdvanceOfPerformanceAndNotRecognisedAsRevenueDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CashReceivedInAdvanceOfPerformanceAndNotRecognisedAsRevenueDuringPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Cash received in advance of performance and not recognised as revenue during the period" } } }, "auth_ref": [] }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesAxis", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en-us": { "role": { "label": "Categories of related parties [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_CategoriesOfRelatedPartiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CategoriesOfRelatedPartiesDomain", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "auth_ref": [ "r53" ] }, "ifrs-full_ChangesInEquity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ChangesInEquity", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Total contribution by and distributions to owners" } }, "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } } }, "auth_ref": [ "r4" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ifrs-full_ClassesOfAssetsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfAssetsAxis", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Classes of assets [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r67", "r68", "r116", "r127" ] }, "ifrs-full_ClassesOfAssetsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfAssetsDomain", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of assets' axis if no other member is used." } } }, "auth_ref": [ "r67", "r116", "r127" ] }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsAxis", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Classes of financial instruments [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r159", "r161", "r162", "r163" ] }, "ifrs-full_ClassesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfFinancialInstrumentsDomain", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r159", "r161", "r162", "r163" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r259" ] }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfIntangibleAssetsAndGoodwillDomain", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r259" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r47" ] }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfPropertyPlantAndEquipmentDomain", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Classes of property, plant and equipment' axis if no other member is used." } } }, "auth_ref": [ "r47" ] }, "ifrs-full_ClassesOfShareCapitalAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfShareCapitalAxis", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails3", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Classes of share capital [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_ClassesOfShareCapitalDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ClassesOfShareCapitalDomain", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails3", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } } }, "auth_ref": [ "r24" ] }, "ifrs-full_ComponentsOfEquityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityAxis", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1", "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative", "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Components of equity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComponentsOfEquityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfEquityDomain", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1", "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative", "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Items that will or may be reclassified subsequently to profit or loss:" } } }, "auth_ref": [] }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total comprehensive loss attributable to the owners of the parent", "label": "Total comprehensive loss" } }, "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } } }, "auth_ref": [ "r0", "r28" ] }, "ifrs-full_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ComputerEquipmentMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r251" ] }, "bdrx_ConsiderationExercisePrefundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationExercisePrefundedWarrants", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration exercise pre-funded warrants" } } }, "auth_ref": [] }, "bdrx_ConsiderationExerciseSeriesESeriesFWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationExerciseSeriesESeriesFWarrants", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration exercise series E & series F warrants" } } }, "auth_ref": [] }, "bdrx_ConsiderationForPrivatePlacements": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForPrivatePlacements", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for Private Placements" } } }, "auth_ref": [] }, "bdrx_ConsiderationForRegisteredDirectOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForRegisteredDirectOffering", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for Registered Direct Offering" } } }, "auth_ref": [] }, "bdrx_ConsiderationForRegisteredOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForRegisteredOffering", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for Registered Offering" } } }, "auth_ref": [] }, "bdrx_ConsiderationForSharesIssuedOnPurchaseIntangibleAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForSharesIssuedOnPurchaseIntangibleAsset", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for Shares issued on purchase Intangible asset" } } }, "auth_ref": [] }, "bdrx_ConsiderationForSharesIssuedOnWarrantInducement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForSharesIssuedOnWarrantInducement", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for shares issued on warrant inducement" } } }, "auth_ref": [] }, "bdrx_ConsiderationForSharesIssuedUnderEloc": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ConsiderationForSharesIssuedUnderEloc", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Consideration for Shares issued under ELOC" } } }, "auth_ref": [] }, "dei_ContactPersonnelName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "ContactPersonnelName", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Contact Personnel Name", "documentation": "Name of contact personnel" } } }, "auth_ref": [] }, "bdrx_ContingentLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContingentLiability", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Contingent liability" } } }, "auth_ref": [] }, "ifrs-full_ContractAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ContractAssets", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contractual assets, beginning", "periodEndLabel": "Contractual assets, ending", "label": "Contract assets" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s right to consideration in exchange for goods or services that the entity has transferred to a customer, when that right is conditioned on something other than the passage of time (for example, the entity\u2019s future performance)." } } }, "auth_ref": [ "r117", "r119" ] }, "ifrs-full_ContractLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ContractLiabilities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Contractual liabilities, beginning", "periodEndLabel": "Contractual liabilities, ending", "label": "Contract liabilities" } }, "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } } }, "auth_ref": [ "r117", "r119" ] }, "bdrx_ContractualAssetsAmountsIncludedInContractLiabilitiesThatWasRecognisedAsGrantIncomeAndNettedAgainstRelevantExpensesInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualAssetsAmountsIncludedInContractLiabilitiesThatWasRecognisedAsGrantIncomeAndNettedAgainstRelevantExpensesInPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Amounts included in contract liabilities that was recognised as grant income and netted against the relevant expenses in the period" } } }, "auth_ref": [] }, "bdrx_ContractualAssetsForeignExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualAssetsForeignExchange", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Foreign exchange" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesAmountsIncludedInContractLiabilitiesThatWasRecognisedAsGrantIncomeAndNettedAgainstRelevantExpensesInPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesAmountsIncludedInContractLiabilitiesThatWasRecognisedAsGrantIncomeAndNettedAgainstRelevantExpensesInPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Amounts included in contract liabilities that was recognised as grant income and netted against the relevant expenses in the period" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesAmountsIncludedInContractLiabilitiesThatWasRecognisedAsRevenueDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesAmountsIncludedInContractLiabilitiesThatWasRecognisedAsRevenueDuringPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Amounts included in contract liabilities that was recognised as revenue during the period" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesCashReceivedInAdvanceOfPerformanceAndNotRecognisedAsRevenueDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesCashReceivedInAdvanceOfPerformanceAndNotRecognisedAsRevenueDuringPeriod", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Cash received in advance of performance and not recognised as revenue during the period" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesExcessOfRevenueRecognisedOverCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesExcessOfRevenueRecognisedOverCash", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Excess of revenue recognised over cash" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesForeignExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesForeignExchange", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Foreign exchange" } } }, "auth_ref": [] }, "bdrx_ContractualLiabilitiesTransfersInPeriodFromContractAssetsToTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLiabilitiesTransfersInPeriodFromContractAssetsToTradeReceivables", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual liabilities, Transfers in the period from contract assets to trade receivables" } } }, "auth_ref": [] }, "bdrx_ContractualLifeTerm": { "xbrltype": "durationItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ContractualLifeTerm", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Contractual life", "documentation": "It represents as a contractual life term." } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithElocAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithElocAgreement", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with ELOC agreement" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 21 December 2023" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue2": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue2", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 26 May 2023" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue3": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue3", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 15 February 2023" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue4": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue4", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 22 July 2024" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue5": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue5", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 22 May 2024" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue6": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue6", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 19 December 2025" } } }, "auth_ref": [] }, "bdrx_CostsAssociatedWithShareIssue7": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsAssociatedWithShareIssue7", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Costs associated with share issue on 15 May 2025" } } }, "auth_ref": [] }, "bdrx_CostsOfRaisingFundsOnPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CostsOfRaisingFundsOnPublicOffering", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails1" ], "lang": { "en-us": { "role": { "label": "Transaction costs", "documentation": "The costs of funds raised through public offering." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "auth_ref": [] }, "ifrs-full_CurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssets", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "label": "Current assets [Default Label]" } }, "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } } }, "auth_ref": [ "r18", "r102", "r207" ] }, "ifrs-full_CurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentAssetsAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "auth_ref": [] }, "ifrs-full_CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentBorrowingsAndCurrentPortionOfNoncurrentBorrowings", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Current borriwings" } }, "en": { "role": { "documentation": "The amount of current borrowings and current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_CurrentDerivativeFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentDerivativeFinancialLiabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Derivative financial liability", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "verboseLabel": "Equity settled derivative financial liability" } }, "en": { "role": { "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r245" ] }, "bdrx_CurrentDerivativeFinancialLiabilities1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CurrentDerivativeFinancialLiabilities1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Equity settled derivative financial liability" } } }, "auth_ref": [] }, "ifrs-full_CurrentFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentFinancialLiabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial liabilities, excluding loans and borrowings, classified as financial liabilities measured at amortised cost", "label": "Current financial liabilities" } }, "en": { "role": { "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r155" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ifrs-full_CurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current liabilities", "label": "Current liabilities [Default Label]" } }, "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } } }, "auth_ref": [ "r19", "r104", "r207" ] }, "ifrs-full_CurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentLiabilitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "auth_ref": [] }, "ifrs-full_CurrentProvisions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentProvisions", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Provisions", "verboseLabel": "Current portion" } }, "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } } }, "auth_ref": [ "r12" ] }, "ifrs-full_CurrentTaxAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTaxAssetsCurrent", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Current taxation receivable" } }, "en": { "role": { "documentation": "The current amount of current tax assets. [Refer: Current tax assets]" } } }, "auth_ref": [ "r13" ] }, "bdrx_CurrentTaxCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CurrentTaxCredit", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current tax credit" } } }, "auth_ref": [] }, "bdrx_CurrentTaxCreditedToIncomeStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CurrentTaxCreditedToIncomeStatement", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current tax (charged)/credited to the income statement" } } }, "auth_ref": [] }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "label": "Current tax credit" } } }, "auth_ref": [] }, "ifrs-full_CurrentTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "CurrentTradeReceivables", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade receivables", "label": "Current trade receivables" } }, "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } } }, "auth_ref": [ "r185", "r187" ] }, "bdrx_CustomersAMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "CustomersAMember", "presentation": [ "http://biodexapharma.com/role/RevenueDetails2" ], "lang": { "en-us": { "role": { "label": "Customer A [member]" } } }, "auth_ref": [] }, "bdrx_DARAOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DARAOptionsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "DARA Options [member]" } } }, "auth_ref": [] }, "bdrx_DARAWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DARAWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "DARA Warrants [member]" } } }, "auth_ref": [] }, "bdrx_DDeferredSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DDeferredSharesMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "\u0091D\u0092 deferred shares [Member]" } } }, "auth_ref": [] }, "bdrx_DateOfGrantAxis": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DateOfGrantAxis", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Date Of Grant [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "bdrx_DateOfGrantDomain": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DateOfGrantDomain", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "auth_ref": [] }, "bdrx_DeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsideration", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred consideration", "label": "DeferredConsideration" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationCurrent", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred consideration", "label": "Current portion" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationForeignExchange": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationForeignExchange", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Foreign exchange" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationInterestExpense", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationNonCurrent", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred consideration", "verboseLabel": "Less: non-current portion" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationOnAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationOnAcquisition", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Deferred consideration on acquisition" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationOnAcquisitionOfLicence": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationOnAcquisitionOfLicence", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "On acquisition of licence" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationOpeningProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationOpeningProvision", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Opening provision at 1 January" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationPayments", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetails" ], "lang": { "en-us": { "role": { "label": "Payments" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationTextBlock", "presentation": [ "http://biodexapharma.com/role/DeferredConsideration" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred consideration", "label": "DeferredConsiderationTextBlock" } } }, "auth_ref": [] }, "bdrx_DeferredConsiderationsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredConsiderationsMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Deferred considerations [member]" } } }, "auth_ref": [] }, "bdrx_DeferredIncome1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredIncome1", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred revenue", "label": "DeferredIncome1" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeAbstract", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "label": "Deferred tax credit" } } }, "auth_ref": [] }, "ifrs-full_DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DeferredTaxExpenseIncomeRelatingToOriginationAndReversalOfTemporaryDifferences", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Reversal of temporary differences", "label": "Deferred tax expense (income) relating to origination and reversal of temporary differences" } }, "en": { "role": { "documentation": "The amount of deferred tax expense or income relating to the creation or reversal of temporary differences. [Refer: Temporary differences [member]; Deferred tax expense (income)]" } } }, "auth_ref": [ "r190" ] }, "ifrs-full_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en-us": { "role": { "label": "Deferred revenue" } }, "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } } }, "auth_ref": [ "r14", "r16", "r38" ] }, "bdrx_DeferredTaxNotRecognised": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DeferredTaxNotRecognised", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Deferred tax not recognised" } } }, "auth_ref": [] }, "bdrx_DepreciationOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DepreciationOfPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation of property, plant and equipment", "label": "DepreciationOfPropertyPlantAndEquipment" } } }, "auth_ref": [] }, "bdrx_DepreciationOfRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DepreciationOfRightOfUseAsset", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation of right of use asset", "label": "DepreciationOfRightOfUseAsset" } } }, "auth_ref": [] }, "ifrs-full_DepreciationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationPropertyPlantAndEquipment", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Charge for the year" } }, "en": { "role": { "documentation": "The amount of depreciation of property, plant and equipment. [Refer: Depreciation and amortisation expense; Property, plant and equipment]" } } }, "auth_ref": [ "r45", "r48" ] }, "ifrs-full_DepreciationRightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DepreciationRightofuseAssets", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation of right of use asset" } }, "en": { "role": { "documentation": "The amount of depreciation of right-of-use assets. [Refer: Depreciation and amortisation expense; Right-of-use assets]" } } }, "auth_ref": [ "r124" ] }, "ifrs-full_DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionAndCarryingAmountOfIntangibleAssetsWithIndefiniteUsefulLife", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2" ], "lang": { "en-us": { "role": { "label": "Useful economic lives" } }, "en": { "role": { "documentation": "The description of intangible assets with indefinite useful life, supporting the assessment of indefinite useful life. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r75" ] }, "bdrx_DescriptionOStockholdersEquityNoteStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOStockholdersEquityNoteStockSplit", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of stock split" } } }, "auth_ref": [] }, "bdrx_DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForBasisForConsolidationExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis for consolidation" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForBusinessCombinationsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business combinations and externally acquired intangible assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for business combinations. [Refer: Total for all business combinations [member]]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForDeferredIncomeTaxExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Deferred taxation" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for deferred income tax. [Refer: Deferred tax expense (income)]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Retirement benefits: defined contribution schemes" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForFinancialAssetsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Financial assets and liabilities" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Foreign currency" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for foreign currency translation." } } }, "auth_ref": [ "r244" ] }, "bdrx_DescriptionOfAccountingPolicyForGoingConcernExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForGoingConcernExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Going concern \u2013 material uncertainty" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForImpairmentOfNonfinancialAssetsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Impairment of non-financial assets" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for the impairment of non-financial assets. [Refer: Financial assets]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Internally generated intangible assets (development costs)" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Share capital", "label": "Description of accounting policy for issued capital [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "Description of accounting policy for leases [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } } }, "auth_ref": [ "r244" ] }, "bdrx_DescriptionOfAccountingPolicyForPatentsAndTrademarksExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfAccountingPolicyForPatentsAndTrademarksExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Patents and trademarks" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment", "label": "Description of accounting policy for property, plant and equipment [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Provisions", "label": "Description of accounting policy for provisions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Description of accounting policy for recognition of revenue [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r244" ] }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based payments", "label": "Description of accounting policy for share-based payment transactions [text block]" } }, "en": { "role": { "documentation": "The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Types of share-based payment arrangements [domain]]" } } }, "auth_ref": [ "r244" ] }, "bdrx_DescriptionOfAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfAccountingPolicyTextBlock", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Taxation", "label": "DescriptionOfAccountingPolicyTextBlock" } } }, "auth_ref": [] }, "bdrx_DescriptionOfDeferredTaxAsset": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfDeferredTaxAsset", "presentation": [ "http://biodexapharma.com/role/DeferredTaxDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Description of deferred tax asset", "documentation": "The information of deferred tax asset." } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Volatility" } }, "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DescriptionOfInputsUsedInFairValueMeasurementAssets": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfInputsUsedInFairValueMeasurementAssets", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Significant unobservable input(s)" } }, "en": { "role": { "documentation": "The description of inputs used in the fair value measurement of assets. Inputs are the assumptions that market participants would use when pricing the asset, including assumptions about risk such as the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and the risk inherent in the inputs to the valuation technique." } } }, "auth_ref": [ "r114" ] }, "bdrx_DescriptionOfInputsUsedInFairValueMeasurementAssets1": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfInputsUsedInFairValueMeasurementAssets1", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant unobservable input(s)", "documentation": "The description of inputs used in the fair value measurement of assets. Inputs are the assumptions that market participants would use when pricing the asset, including assumptions about risk such as the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and the risk inherent in the inputs to the valuation technique.", "label": "DescriptionOfInputsUsedInFairValueMeasurementAssets1" } } }, "auth_ref": [] }, "bdrx_DescriptionOfInputsUsedInFairValueMeasurementAssets2": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfInputsUsedInFairValueMeasurementAssets2", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant unobservable input(s)", "documentation": "The description of inputs used in the fair value measurement of assets. Inputs are the assumptions that market participants would use when pricing the asset, including assumptions about risk such as the risk inherent in a particular valuation technique used to measure fair value (such as a pricing model) and the risk inherent in the inputs to the valuation technique.", "label": "DescriptionOfInputsUsedInFairValueMeasurementAssets2" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfNatureAndPurposeOfReservesWithinEquity": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfNatureAndPurposeOfReservesWithinEquity", "presentation": [ "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Description of nature and purpose of reserves within equity" } }, "en": { "role": { "documentation": "The description of the nature and purpose of reserves within equity. [Refer: Other reserves]" } } }, "auth_ref": [ "r25" ] }, "ifrs-full_DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfNatureOfEntitysOperationsAndPrincipalActivities", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Summary description", "verboseLabel": "Nature of Operation" } }, "en": { "role": { "documentation": "The description of the nature of the entity's operations and principal activities." } } }, "auth_ref": [ "r6" ] }, "ifrs-full_DescriptionOfOptionPricingModelShareOptionsGranted": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfOptionPricingModelShareOptionsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Option pricing models used" } }, "en": { "role": { "documentation": "The description of the option pricing model used for share options granted. [Refer: Option pricing model [member]]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DescriptionOfReasonsForFairValueMeasurementAssets": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfReasonsForFairValueMeasurementAssets", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Relationship of unobservable inputs to fair value" } }, "en": { "role": { "documentation": "The description of the reasons for the fair value measurement of assets." } } }, "auth_ref": [ "r112" ] }, "bdrx_DescriptionOfReasonsForFairValueMeasurementAssets1": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfReasonsForFairValueMeasurementAssets1", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Relationship of unobservable inputs to fair value", "documentation": "The description of the reasons for the fair value measurement of assets.", "label": "DescriptionOfReasonsForFairValueMeasurementAssets1" } } }, "auth_ref": [] }, "bdrx_DescriptionOfReasonsForFairValueMeasurementAssets2": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DescriptionOfReasonsForFairValueMeasurementAssets2", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Relationship of unobservable inputs to fair value", "documentation": "The description of the reasons for the fair value measurement of assets.", "label": "DescriptionOfReasonsForFairValueMeasurementAssets2" } } }, "auth_ref": [] }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Risk free rate" } }, "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } } }, "auth_ref": [ "r148" ] }, "ifrs-full_DescriptionOfUsefulLifePropertyPlantAndEquipment": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfUsefulLifePropertyPlantAndEquipment", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3" ], "lang": { "en-us": { "role": { "label": "Description of useful life, property, plant and equipment" } }, "en": { "role": { "documentation": "Description of useful life used for property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r41" ] }, "ifrs-full_DescriptionOfValuationTechniquesUsedInFairValueMeasurementAssets": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DescriptionOfValuationTechniquesUsedInFairValueMeasurementAssets", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Valuation technique (s) and key input(s)" } }, "en": { "role": { "documentation": "The description of the valuation techniques (for example, the market approach, cost approach and income approach) used for the fair value measurement of assets. [Refer: Valuation techniques used in fair value measurement [domain]; Cost approach [member]; Income approach [member]; Market approach [member]]" } } }, "auth_ref": [ "r114" ] }, "ifrs-full_DilutedEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DilutedEarningsLossPerShare", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Diluted loss perordinary share", "verboseLabel": "Diluted loss per share" } }, "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } } }, "auth_ref": [ "r64", "r65" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [] }, "bdrx_DisclosureCapitalCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureCapitalCommitmentsAbstract", "lang": { "en-us": { "role": { "label": "Capital Commitments" } } }, "auth_ref": [] }, "bdrx_DisclosureCriticalAccountingEstimatesAndJudgementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureCriticalAccountingEstimatesAndJudgementsAbstract", "lang": { "en-us": { "role": { "label": "Critical Accounting Estimates And Judgements" } } }, "auth_ref": [] }, "bdrx_DisclosureDeferredConsiderationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureDeferredConsiderationAbstract", "lang": { "en-us": { "role": { "label": "Deferred Consideration" } } }, "auth_ref": [] }, "bdrx_DisclosureDeferredTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureDeferredTaxAbstract", "lang": { "en-us": { "role": { "label": "Deferred Tax" } } }, "auth_ref": [] }, "bdrx_DisclosureDerivativeFinancialLiabilityCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureDerivativeFinancialLiabilityCurrentAbstract", "lang": { "en-us": { "role": { "label": "Derivative Financial Liability Current", "verboseLabel": "Derivative Financial Liability - Current" } } }, "auth_ref": [] }, "bdrx_DisclosureIntangibleAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureIntangibleAssetsAbstract", "lang": { "en-us": { "role": { "label": "Intangible Assets" } } }, "auth_ref": [] }, "bdrx_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "bdrx_DisclosureLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureLossPerShareAbstract", "lang": { "en-us": { "role": { "label": "Loss Per Share" } } }, "auth_ref": [] }, "bdrx_DisclosureOfAverageNumberOfStaffEmployeeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfAverageNumberOfStaffEmployeeExplanatory", "presentation": [ "http://biodexapharma.com/role/StaffCostsTables" ], "lang": { "en-us": { "role": { "label": "Schedule for average number of employed staff" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfBorrowingsExplanatory", "presentation": [ "http://biodexapharma.com/role/Borrowings" ], "lang": { "en-us": { "role": { "verboseLabel": "Borrowings", "label": "Disclosure of borrowings [text block]" } }, "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r241" ] }, "bdrx_DisclosureOfCapitalCommitmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfCapitalCommitmentsExplanatory", "presentation": [ "http://biodexapharma.com/role/CapitalCommitments" ], "lang": { "en-us": { "role": { "label": "Capital commitments" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotes" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents and cash flow supporting notes" } }, "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfChangesInAccountingPoliciesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfChangesInAccountingPoliciesExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Accounting policies" } }, "en": { "role": { "documentation": "The disclosure of changes made to accounting policies by the entity." } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfCompositionOfGroupExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfCompositionOfGroupExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of entities" } }, "en": { "role": { "documentation": "The disclosure of the composition of the group (the parent and all its subsidiaries). [Refer: Total for all subsidiaries [member]; Parent [member]]" } } }, "auth_ref": [ "r97" ] }, "bdrx_DisclosureOfConsolidatedFinancialAssetsAndLiabilitiesValuedAtFairValueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfConsolidatedFinancialAssetsAndLiabilitiesValuedAtFairValueExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of consolidated financial assets and liabilities at fair value" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfContingentLiabilitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfContingentLiabilitiesExplanatory", "presentation": [ "http://biodexapharma.com/role/ContingentLiabilities" ], "lang": { "en-us": { "role": { "label": "Contingent liabilities" } }, "en": { "role": { "documentation": "The disclosure of contingent liabilities. [Refer: Classes of contingent liabilities [domain]]" } } }, "auth_ref": [ "r71" ] }, "bdrx_DisclosureOfCriticalAccountingEstimatesAndJudgements": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfCriticalAccountingEstimatesAndJudgements", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgements" ], "lang": { "en-us": { "role": { "label": "Critical accounting estimates and judgements" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDeferredTaxeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDeferredTaxeExplanatory", "presentation": [ "http://biodexapharma.com/role/DeferredTax" ], "lang": { "en-us": { "role": { "label": "Deferred tax" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDepreciationRatesOfPropertyPlantAndEquipmentTableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDepreciationRatesOfPropertyPlantAndEquipmentTableExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of depreciation rates of property, plant and equipment" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDerivativeFinancialLiabilityCurrentExplanatory", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrent" ], "lang": { "en-us": { "role": { "label": "Derivative financial liability \u2013 current" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of cash and cash equivalents" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutComponentsOfIncomeTaxExpenseBenefitExplanatory", "presentation": [ "http://biodexapharma.com/role/TaxationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of components of income tax expense" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutDifferenceBetweenActualTaxChargeAndStandardTateOfCorporationTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutDifferenceBetweenActualTaxChargeAndStandardTateOfCorporationTaxExplanatory", "presentation": [ "http://biodexapharma.com/role/TaxationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of difference between actual tax charge and the standard rate of corporation tax" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutEarningsPerShareExplanatory", "presentation": [ "http://biodexapharma.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of loss per share" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutFinanceIncomeExpenseExplanatory", "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseTables" ], "lang": { "en-us": { "role": { "label": "Schedule of finance income" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutMarketRentalRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutMarketRentalRatesExplanatory", "presentation": [ "http://biodexapharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of market rental rates" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of detailed information about property, plant and equipment" } }, "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r47" ] }, "bdrx_DisclosureOfDetailedInformationAboutShareIssuesNetOfCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutShareIssuesNetOfCostsExplanatory", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of cash inflows from an equity financing transaction" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutStaffCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutStaffCostsExplanatory", "presentation": [ "http://biodexapharma.com/role/StaffCostsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of staff costs" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatory", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of trade and other payables" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationBorrowingsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationBorrowingsExplanatory", "presentation": [ "http://biodexapharma.com/role/BorrowingsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of borrowings" } } }, "auth_ref": [] }, "bdrx_DisclosureOfDetailedInformationProvisionExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfDetailedInformationProvisionExplanatory", "presentation": [ "http://biodexapharma.com/role/ProvisionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of provisions" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "presentation": [ "http://biodexapharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } } }, "auth_ref": [ "r118" ] }, "bdrx_DisclosureOfEarningsPerSharesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfEarningsPerSharesExplanatory", "presentation": [ "http://biodexapharma.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss per share", "label": "DisclosureOfEarningsPerSharesExplanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1", "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } } }, "auth_ref": [ "r116" ] }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of consolidated derivative financial instruments" } }, "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Classes of financial instruments [domain]; At fair value [member]]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfFairValueOfPlanAssetsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFairValueOfPlanAssetsExplanatory", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair value of the asset" } }, "en": { "role": { "documentation": "The disclosure of the fair value of defined benefit plan assets. [Refer: Plan assets [member]; Defined benefit plans [domain]]" } } }, "auth_ref": [ "r50" ] }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpense" ], "lang": { "en-us": { "role": { "label": "Finance income and expense" } }, "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagement" ], "lang": { "en-us": { "role": { "label": "Financial instruments \u2013 risk management" } }, "en": { "role": { "documentation": "The entire disclosure for financial instruments." } } }, "auth_ref": [ "r168" ] }, "ifrs-full_DisclosureOfFinancialInstrumentsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfFinancialInstrumentsTable", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of financial instruments." } } }, "auth_ref": [ "r156", "r161", "r166" ] }, "bdrx_DisclosureOfForeignCurrencyExchangeRatesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfForeignCurrencyExchangeRatesExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of foreign currency exchange rates" } } }, "auth_ref": [] }, "bdrx_DisclosureOfForeignExchangeRiskExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfForeignExchangeRiskExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of foreign exchange risk" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfGeographicalAreasExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfGeographicalAreasExplanatory", "presentation": [ "http://biodexapharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of revenue by geographical analysis" } }, "en": { "role": { "documentation": "The disclosure of geographical information." } } }, "auth_ref": [ "r178" ] }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIncomeTaxExplanatory", "presentation": [ "http://biodexapharma.com/role/Taxation" ], "lang": { "en-us": { "role": { "verboseLabel": "Taxation", "label": "Disclosure of income tax [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for income taxes." } } }, "auth_ref": [ "r40" ] }, "ifrs-full_DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIndirectMeasurementOfFairValueOfGoodsOrServicesReceivedShareOptionsGrantedDuringPeriodExplanatory", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair value of options granted" } }, "en": { "role": { "documentation": "The disclosure of information about indirect, by reference to the fair value of the equity instruments granted, measurement of the fair value of goods or services received as consideration for the entity's share options." } } }, "auth_ref": [ "r149" ] }, "bdrx_DisclosureOfInformationAboutKeyManagementPersonnel": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfInformationAboutKeyManagementPersonnel", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of information about key management personnel" } } }, "auth_ref": [] }, "bdrx_DisclosureOfIntangibleAssetExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfIntangibleAssetExplanatory", "presentation": [ "http://biodexapharma.com/role/IntangibleAssets" ], "lang": { "en-us": { "role": { "verboseLabel": "Intangible assets", "label": "DisclosureOfIntangibleAssetExplanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeExplanatory", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of intangibles assets useful economic lives" } }, "en": { "role": { "documentation": "The disclosure of intangible assets with an indefinite useful life. [Refer: Intangible assets with indefinite useful life]" } } }, "auth_ref": [ "r75" ] }, "bdrx_DisclosureOfIssuedCapital1Explanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfIssuedCapital1Explanatory", "presentation": [ "http://biodexapharma.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule of detailed information about share capital" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfIssuedCapitalExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfIssuedCapitalExplanatory", "presentation": [ "http://biodexapharma.com/role/ShareCapital" ], "lang": { "en-us": { "role": { "verboseLabel": "Share capital", "label": "Disclosure of issued capital [text block]" } }, "en": { "role": { "documentation": "The disclosure of issued capital. [Refer: Issued capital]" } } }, "auth_ref": [ "r241" ] }, "bdrx_DisclosureOfLeaseExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfLeaseExplanatory", "presentation": [ "http://biodexapharma.com/role/Leases" ], "lang": { "en-us": { "role": { "verboseLabel": "Leases", "label": "DisclosureOfLeaseExplanatory" } } }, "auth_ref": [] }, "bdrx_DisclosureOfLowValueLeasesExpensed": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfLowValueLeasesExpensed", "presentation": [ "http://biodexapharma.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "label": "Low value leases expensed in year" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfMajorCustomersTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfMajorCustomersTable", "presentation": [ "http://biodexapharma.com/role/RevenueDetails2" ], "lang": { "en-us": { "role": { "label": "Disclosure of major customers [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the entity's major customers." } } }, "auth_ref": [ "r179" ] }, "bdrx_DisclosureOfMaturitiesOfFinancialInstrumentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfMaturitiesOfFinancialInstrumentsExplanatory", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of contractual maturities of financial liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfShareOptionsExplanatory", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsTables" ], "lang": { "en-us": { "role": { "label": "Details of all share options granted under the schemes are set out below" } }, "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of share options. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r146" ] }, "bdrx_DisclosureOfOrdinaryAndDeferredShares": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfOrdinaryAndDeferredShares", "presentation": [ "http://biodexapharma.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule of ordinary and deferred shares" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfProfitLossFromOperatingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfProfitLossFromOperatingActivitiesExplanatory", "presentation": [ "http://biodexapharma.com/role/LossFromOperations" ], "lang": { "en-us": { "role": { "label": "Loss from operations" } }, "en": { "role": { "documentation": "The disclosure of profit (loss) from operating activities. [Refer: Profit (loss) from operating activities]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } } }, "auth_ref": [ "r47" ] }, "bdrx_DisclosureOfPropertyPlantAndEquipmentsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfPropertyPlantAndEquipmentsExplanatory", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipment" ], "lang": { "en-us": { "role": { "verboseLabel": "Property, plant and equipment", "label": "DisclosureOfPropertyPlantAndEquipmentsExplanatory" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRangeOfExercisePricesOfOutstandingShareOptionsExplanatory", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding" } }, "en": { "role": { "documentation": "The disclosure of the range of exercise prices for outstanding share options." } } }, "auth_ref": [ "r147" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInBiologicalAssetsTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInBiologicalAssetsTable", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in biological assets [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in biological assets." } } }, "auth_ref": [ "r80" ] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of changes in intangible assets and goodwill" } }, "en": { "role": { "documentation": "The disclosure of the reconciliation of changes in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r259" ] }, "bdrx_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory1": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillExplanatory1", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of changes in bank loan liabilities" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfChangesInIntangibleAssetsAndGoodwillTable", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of changes in intangible assets and goodwill [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of changes in intangible assets and goodwill." } } }, "auth_ref": [ "r259" ] }, "ifrs-full_DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReconciliationOfLiabilitiesArisingFromFinancingActivitiesTable", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Disclosure of reconciliation of liabilities arising from financing activities [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the reconciliation of liabilities arising from financing activities." } } }, "auth_ref": [ "r204" ] }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRelatedPartyExplanatory", "presentation": [ "http://biodexapharma.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "label": "Related party transactions" } }, "en": { "role": { "documentation": "The entire disclosure for related parties." } } }, "auth_ref": [ "r54" ] }, "bdrx_DisclosureOfReservesAndOtherEquityInterest1Explanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfReservesAndOtherEquityInterest1Explanatory", "presentation": [ "http://biodexapharma.com/role/ReservesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of reserves" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfReservesAndOtherEquityInterestExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfReservesAndOtherEquityInterestExplanatory", "presentation": [ "http://biodexapharma.com/role/Reserves" ], "lang": { "en-us": { "role": { "label": "Reserves" } }, "en": { "role": { "documentation": "The disclosure of reserves within equity. [Refer: Other reserves [member]]" } } }, "auth_ref": [ "r25" ] }, "bdrx_DisclosureOfRetirementBenefitsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfRetirementBenefitsExplanatory", "presentation": [ "http://biodexapharma.com/role/RetirementBenefits" ], "lang": { "en-us": { "role": { "label": "Retirement benefits" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfRevenueExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRevenueExplanatory", "presentation": [ "http://biodexapharma.com/role/Revenue" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "Disclosure of revenue [text block]" } }, "en": { "role": { "documentation": "The entire disclosure for revenue." } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to the risk management strategy in relation to hedge accounting." } } }, "auth_ref": [ "r153", "r181" ] }, "bdrx_DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfScheduleProfitLossFromOperatingActivitiesExplanatory", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of loss from operations" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "presentation": [ "http://biodexapharma.com/role/Share-basedPayments" ], "lang": { "en-us": { "role": { "label": "Share-based payments" } }, "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } } }, "auth_ref": [ "r138" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "presentation": [ "http://biodexapharma.com/role/Subsidiaries" ], "lang": { "en-us": { "role": { "label": "Subsidiaries" } }, "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r60", "r63", "r111" ] }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTable", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Disclosure of subsidiaries [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to subsidiaries." } } }, "auth_ref": [ "r60", "r63", "r111" ] }, "bdrx_DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesTableExplanatory", "presentation": [ "http://biodexapharma.com/role/SubsidiariesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of subsidiaries" } } }, "auth_ref": [] }, "bdrx_DisclosureOfStaffCostsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfStaffCostsExplanatory", "presentation": [ "http://biodexapharma.com/role/StaffCosts" ], "lang": { "en-us": { "role": { "label": "Staff costs" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "presentation": [ "http://biodexapharma.com/role/DeferredTaxTables" ], "lang": { "en-us": { "role": { "label": "Schedule of unused tax losses carried forward" } }, "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } } }, "auth_ref": [ "r39" ] }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayables" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade and other payables", "label": "Disclosure of trade and other payables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } } }, "auth_ref": [ "r241" ] }, "bdrx_DisclosureOfTradeAndOtherReceivableTableExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfTradeAndOtherReceivableTableExplanatory", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivablesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of trade and other receivables" } } }, "auth_ref": [] }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivables" ], "lang": { "en-us": { "role": { "verboseLabel": "Trade and other receivables", "label": "Disclosure of trade and other receivables [text block]" } }, "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } } }, "auth_ref": [ "r241" ] }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } } }, "auth_ref": [ "r53" ] }, "bdrx_DisclosureOfUltimateControllingPartyExplanatory": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOfUltimateControllingPartyExplanatory", "presentation": [ "http://biodexapharma.com/role/UltimateControllingParty" ], "lang": { "en-us": { "role": { "label": "Ultimate controlling party" } } }, "auth_ref": [] }, "bdrx_DisclosureOffCondensedFinancialStatementsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureOffCondensedFinancialStatementsTableTextBlock", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of condensed financial statements" } } }, "auth_ref": [] }, "bdrx_DisclosurePostBalanceSheetEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosurePostBalanceSheetEventsAbstract", "lang": { "en-us": { "role": { "label": "Post Balance Sheet Events" } } }, "auth_ref": [] }, "bdrx_DisclosurePostBalanceSheetEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosurePostBalanceSheetEventsTextBlock", "presentation": [ "http://biodexapharma.com/role/PostBalanceSheetEvents" ], "lang": { "en-us": { "role": { "verboseLabel": "Post Balance Sheet Events", "label": "DisclosurePostBalanceSheetEventsTextBlock" } } }, "auth_ref": [] }, "bdrx_DisclosurePropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosurePropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property Plant And Equipment" } } }, "auth_ref": [] }, "bdrx_DisclosureProvisionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureProvisionsAbstract", "lang": { "en-us": { "role": { "verboseLabel": "Provisions" } } }, "auth_ref": [] }, "bdrx_DisclosureRetirementBenefitsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureRetirementBenefitsAbstract", "lang": { "en-us": { "role": { "label": "Retirement Benefits" } } }, "auth_ref": [] }, "bdrx_DisclosureStaffCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureStaffCostsAbstract", "lang": { "en-us": { "role": { "label": "Staff Costs" } } }, "auth_ref": [] }, "bdrx_DisclosureUltimateControllingPartyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "DisclosureUltimateControllingPartyAbstract", "lang": { "en-us": { "role": { "label": "Ultimate Controlling Party" } } }, "auth_ref": [] }, "bdrx_Disposal": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Disposal", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Disposal", "label": "Disposal [Default Label]" } } }, "auth_ref": [] }, "bdrx_Disposals": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Disposals", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Disposals", "label": "Disposals [Default Label]" } } }, "auth_ref": [] }, "ifrs-full_DisposalsIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisposalsIntangibleAssetsAndGoodwill", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal" } }, "en": { "role": { "documentation": "The decrease in intangible assets and goodwill resulting from disposals. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r257" ] }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "DisposalsPropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Disposals" } }, "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r44" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r233" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r231", "r233", "r234" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r231", "r233", "r234", "r236" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r232" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r220" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r233" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r233" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r235" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r223" ] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "bdrx_EarningsLossPerShareFromContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "EarningsLossPerShareFromContinuingOperationsAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Continuing operations" } } }, "auth_ref": [] }, "ifrs-full_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EarningsPerShareAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Loss per share" } } }, "auth_ref": [] }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Exchange (losses)/gains on cash and cash equivalents" } }, "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } } }, "auth_ref": [ "r85", "r86" ] }, "bdrx_EffectOfRdRelief": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "EffectOfRdRelief", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Effect of R&D relief" } } }, "auth_ref": [] }, "bdrx_EmtoraMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "EmtoraMember", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Emtora [Member]" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityAddressesAddressTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesAddressTypeAxis", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses, Address Type [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "dei_EntityAddressesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesLineItems", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressesTable", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Addresses [Table]", "documentation": "Container of address information for the entity" } } }, "auth_ref": [ "r222" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r226" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r222" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r222" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r240" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r222" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r237" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r234" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r222" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r222" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r222" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r222" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r238" ] }, "ifrs-full_Equity": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Equity", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity", "periodStartLabel": "At 1 January 2023", "periodEndLabel": "At 31 December 2023", "label": "Total equity" } }, "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } } }, "auth_ref": [ "r15", "r21", "r93", "r95", "r112", "r113", "r115" ] }, "ifrs-full_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Issued capital and reserves attributable to owners of the parent" } } }, "auth_ref": [] }, "ifrs-full_EquityAndLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "EquityAndLiabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total equity and liabilities", "label": "Equity and liabilities" } }, "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } } }, "auth_ref": [ "r15" ] }, "bdrx_EquityLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "EquityLineOfCredit", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Line of Credit" } } }, "auth_ref": [] }, "bdrx_EquityLineOfCreditUndraw": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "EquityLineOfCreditUndraw", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Equity Line of Credit undraw" } } }, "auth_ref": [] }, "bdrx_ExcessOfRevenueRecognisedOverCash": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExcessOfRevenueRecognisedOverCash", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Excess of revenue recognised over cash" } } }, "auth_ref": [] }, "bdrx_ExchangeGainsArisingOnTranslationOfForeignOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExchangeGainsArisingOnTranslationOfForeignOperations", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_OtherComprehensiveIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Exchange gains arising on translation of foreign operations" } } }, "auth_ref": [] }, "bdrx_ExerciseOfWarrantsTransferToSharePremium": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExerciseOfWarrantsTransferToSharePremium", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants - transfer to share premium" } } }, "auth_ref": [] }, "bdrx_ExercisePrefundedWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExercisePrefundedWarrants", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Exercise pre-funded warrants" } } }, "auth_ref": [] }, "bdrx_ExercisePriceOfOptionsIssuedInYear": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExercisePriceOfOptionsIssuedInYear", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1" ], "lang": { "en-us": { "role": { "label": "Exercise price of options issued in year", "documentation": "The amount of excercise price of option issued in year." } } }, "auth_ref": [] }, "bdrx_ExercisePriceOfWarrantsIssuedInYear": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExercisePriceOfWarrantsIssuedInYear", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Exercise price of warrants issued in year" } } }, "auth_ref": [] }, "bdrx_ExerciseSeriesESeriesFWarrants": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExerciseSeriesESeriesFWarrants", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Exercise Series E & Series F warrants" } } }, "auth_ref": [] }, "bdrx_Exercised": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Exercised", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Exercised", "label": "Exercised [Default Label]" } } }, "auth_ref": [] }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Expected dividend yield" } }, "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } } }, "auth_ref": [ "r148" ] }, "bdrx_ExpectedLifeTerm": { "xbrltype": "durationItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ExpectedLifeTerm", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Expected life", "documentation": "It represents as a expected life term." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "bdrx_FAPProjectsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FAPProjectsMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1" ], "lang": { "en-us": { "role": { "label": "FAP Projects [Member]" } } }, "auth_ref": [] }, "ifrs-full_FeeAndCommissionIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FeeAndCommissionIncomeExpense", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Fees payable to the Company\u2019s auditor for the audit of the parent Company financial statements" } }, "en": { "role": { "documentation": "The amount of income or expense relating to fees and commissions." } } }, "auth_ref": [ "r249" ] }, "bdrx_FeeAndCommissionIncomeExpense1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FeeAndCommissionIncomeExpense1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Fees payable to the Company\u2019s auditor for the audits of the subsidiary financial statements", "documentation": "The amount of income or expense relating to fees and commissions." } } }, "auth_ref": [] }, "bdrx_FeePayableOtherServices": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FeePayableOtherServices", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "- Audit related services", "documentation": "Represents other service amount." } } }, "auth_ref": [] }, "bdrx_FeePayableOtherServices1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FeePayableOtherServices1", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "-\u00a0\u00a0Audit", "documentation": "Represents other service amount." } } }, "auth_ref": [] }, "bdrx_FeesPayableToCompanysPreviousAuditorForAudit": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FeesPayableToCompanysPreviousAuditorForAudit", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "-\u00a0\u00a0Audit related services" } } }, "auth_ref": [] }, "ifrs-full_FinanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceCosts", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0, "order": 3.0 }, "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 9.0 }, "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Finance expense", "label": "Finance expense", "totalLabel": "Total finance expense" } }, "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } } }, "auth_ref": [ "r30" ] }, "ifrs-full_FinanceIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinanceIncome", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 2.0 }, "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 8.0 }, "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Finance income", "negatedLabel": "Finance income", "totalLabel": "Total finance income" } }, "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } } }, "auth_ref": [ "r249" ] }, "bdrx_FinanceIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FinanceIncomeAbstract", "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance income" } } }, "auth_ref": [] }, "bdrx_FinanceLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FinanceLeaseMember", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Finance Lease [member]", "documentation": "This member stands for finance lease." } } }, "auth_ref": [] }, "ifrs-full_FinancialAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialAssets", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Total financial assets" } }, "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]" } } }, "auth_ref": [ "r155", "r159", "r160", "r162", "r212" ] }, "ifrs-full_FinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Total" } }, "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]" } } }, "auth_ref": [ "r155" ] }, "ifrs-full_FinancialLiabilitiesAtAmortisedCost": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FinancialLiabilitiesAtAmortisedCost", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "label": "Total financial liabilities \u2013 amortised cost" } }, "en": { "role": { "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]" } } }, "auth_ref": [ "r167" ] }, "ifrs-full_FixturesAndFittingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "FixturesAndFittingsMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Fixtures and fittings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r192" ] }, "bdrx_ForeignCurrencySensitivityAnalysisMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignCurrencySensitivityAnalysisMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "label": "Foreign currency sensitivity analysis [member]", "documentation": "This member stands for foreign currency sensitivity analysis.=" } } }, "auth_ref": [] }, "bdrx_ForeignExchangeGainslosses": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignExchangeGainslosses", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign exchange losses/(gains)" } } }, "auth_ref": [] }, "bdrx_ForeignExchangeReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignExchangeReserve", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Foreign exchange reserve" } } }, "auth_ref": [] }, "bdrx_ForeignExchangeReserveMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignExchangeReserveMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Foreign Exchange Reserve [Member]" } } }, "auth_ref": [] }, "bdrx_ForeignExchangeRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignExchangeRiskMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2" ], "lang": { "en-us": { "role": { "label": "Foreign exchange risk [member]", "documentation": "This member stands for information by currency." } } }, "auth_ref": [] }, "bdrx_ForeignExchangeTranslation": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ForeignExchangeTranslation", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Foreign exchange translation" } } }, "auth_ref": [] }, "bdrx_FundsRaisedOnPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "FundsRaisedOnPublicOffering", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails1" ], "lang": { "en-us": { "role": { "label": "Gross proceeds", "documentation": "The funds raised through public offering." } } }, "auth_ref": [] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "GBP", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2" ], "lang": { "en-us": { "role": { "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "bdrx_GainLossOfEquitySettledDerivativeFinancialLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "GainLossOfEquitySettledDerivativeFinancialLiability", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails" ], "lang": { "en-us": { "role": { "label": "Gain recognised in finance (income)/expense within the consolidated statement of comprehensive income", "documentation": "The amount of gains from equity settled derivative financial liability." } } }, "auth_ref": [] }, "bdrx_GainRecognisedInFinanceIncomeWithinConsolidatedStatementOfComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "GainRecognisedInFinanceIncomeWithinConsolidatedStatementOfComprehensiveIncome", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Gain recognised in finance income within the consolidated statement of comprehensive income" } } }, "auth_ref": [] }, "ifrs-full_GainsOnChangeInFairValueOfDerivatives": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GainsOnChangeInFairValueOfDerivatives", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Gain on equity settled derivative financial liability" } }, "en": { "role": { "documentation": "The gains resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]" } } }, "auth_ref": [ "r249" ] }, "bdrx_GeneralAndAdministrativeMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "GeneralAndAdministrativeMember", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails1" ], "lang": { "en-us": { "role": { "label": "General and administration [member]", "documentation": "This member stands for general and administrative." } } }, "auth_ref": [] }, "ifrs-full_GeographicalAreasAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasAxis", "presentation": [ "http://biodexapharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "label": "Geographical areas [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r178", "r193", "r208", "r210" ] }, "ifrs-full_GeographicalAreasDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GeographicalAreasDomain", "presentation": [ "http://biodexapharma.com/role/RevenueDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "auth_ref": [ "r178", "r193", "r208", "r210" ] }, "ifrs-full_GoodwillMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "GoodwillMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [member]" } }, "en": { "role": { "documentation": "This member stands for goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r196" ] }, "bdrx_GovernmentAndResearchLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "GovernmentAndResearchLoansMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Government and research loans [member]", "documentation": "This member stands for government and research loans." } } }, "auth_ref": [] }, "bdrx_Grant10Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant10Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 10 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant11Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant11Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 11 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant12Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant12Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 12 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant13Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant13Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 13 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant14Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant14Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 14 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant15Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant15Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 15 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant16Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant16Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 16 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant17Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant17Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 17 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant18Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant18Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 18 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant19Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant19Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 19 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant1Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 1 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant20Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant20Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 20 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant21Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant21Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 21 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant22Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant22Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 22 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant23Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant23Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 23 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant24Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant24Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 24 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant25Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant25Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 25 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant26Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant26Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 26 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant27Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant27Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 27 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant28Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant28Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 28 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant29Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant29Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 29 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant2Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant2Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 2 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant30Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant30Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 30 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant31Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant31Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 31 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant32Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant32Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 32 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant33Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant33Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 33 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant34Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant34Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 34 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant35Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant35Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 35 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant36Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant36Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 36 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant37Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant37Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 37 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant3Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant3Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 3 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant4Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant4Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 4 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant5Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant5Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 5 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant6Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant6Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 6 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant7Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant7Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 7 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant8Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant8Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 8 [Member]" } } }, "auth_ref": [] }, "bdrx_Grant9Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Grant9Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Grant 9 [Member]" } } }, "auth_ref": [] }, "bdrx_GrossGrossGrossCarryingAmountMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "GrossGrossGrossCarryingAmountMember", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Gross Carrying Amount [member]" } } }, "auth_ref": [] }, "bdrx_HaalandUKLimited1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "HaalandUKLimited1Member", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Haaland UK Limited [member]" } } }, "auth_ref": [] }, "bdrx_HaalandUKLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "HaalandUKLimitedMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Haaland UK Limited [Member]" } } }, "auth_ref": [] }, "bdrx_ITAndWebsiteCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ITAndWebsiteCostsMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "IT and website costs [member]", "documentation": "The member stands for IT and website costs." } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r231", "r233", "r234" ] }, "bdrx_IfrsStatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IfrsStatementLineItems", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/AccountingPoliciesDetails1", "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2", "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1", "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4", "http://biodexapharma.com/role/IntangibleAssetsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1", "http://biodexapharma.com/role/LeasesDetails", "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative", "http://biodexapharma.com/role/ReservesDetails", "http://biodexapharma.com/role/RevenueDetails", "http://biodexapharma.com/role/RevenueDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails3", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2", "http://biodexapharma.com/role/StaffCostsDetails1", "http://biodexapharma.com/role/StaffCostsDetails3", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "IfrsStatementLineItems [Line Items]" } } }, "auth_ref": [] }, "bdrx_IfrsStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IfrsStatementTable", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/StaffCostsDetails1", "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "IfrsStatementTable [Table]" } } }, "auth_ref": [] }, "bdrx_ImpairmentOfCommissionPaidInAdvance": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ImpairmentOfCommissionPaidInAdvance", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of commission paid in advance on ELOC" } } }, "auth_ref": [] }, "bdrx_ImpairmentOfElocUpfrontFee": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ImpairmentOfElocUpfrontFee", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment of ELOC upfront fee" } } }, "auth_ref": [] }, "bdrx_ImpairmentOfFinancialAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ImpairmentOfFinancialAsset", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Impairment of financial asset" } } }, "auth_ref": [] }, "bdrx_ImpairmentOfLoan": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ImpairmentOfLoan", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Impairment of loan" } } }, "auth_ref": [] }, "bdrx_IncomeNotTaxable": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncomeNotTaxable", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Income not taxable" } } }, "auth_ref": [] }, "ifrs-full_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "auth_ref": [] }, "bdrx_IncomeStatementLocation1Axis": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncomeStatementLocation1Axis", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/StaffCostsDetails1" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table." } } }, "auth_ref": [] }, "bdrx_IncomeStatementLocation1Domain": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncomeStatementLocation1Domain", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/StaffCostsDetails1" ], "auth_ref": [] }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxExpenseContinuingOperations", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/TaxationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxation", "negatedTerseLabel": "Total tax credit", "label": "Tax expense (income)" } }, "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } } }, "auth_ref": [ "r31", "r34", "r35", "r36", "r57", "r110", "r170" ] }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes received", "label": "Income taxes paid (refund), classified as operating activities" } }, "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } } }, "auth_ref": [ "r88", "r198" ] }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseInCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase/(decrease) in cash and cash equivalents", "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes" } }, "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } } }, "auth_ref": [ "r91" ] }, "ifrs-full_IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughEffectOfChangesInForeignExchangeRatesLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Foreign Exchange" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from the effect of changes in foreign exchange rates. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r90" ] }, "ifrs-full_IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughFinancingCashFlowsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Cash Flows" } }, "en": { "role": { "documentation": "The increase (decrease) in liabilities arising from financing activities resulting from financing cash flows. [Refer: Cash flows from (used in) financing activities; Liabilities arising from financing activities]" } } }, "auth_ref": [ "r89" ] }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based payment charge", "label": "Increase (decrease) through share-based payment transactions, equity" } }, "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } } }, "auth_ref": [ "r3" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsAndGoodwill", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Acquisition" } }, "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill resulting from transfers. [Refer: Intangible assets and goodwill]" } } }, "auth_ref": [ "r258" ] }, "ifrs-full_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Transfer" } }, "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from transfers. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r253" ] }, "bdrx_IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Transfer", "label": "IncreaseDecreaseThroughTransfersPropertyPlantAndEquipment1" } } }, "auth_ref": [] }, "bdrx_IncreaseThroughInterestAccruingInPeriodLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncreaseThroughInterestAccruingInPeriodLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Interest accruing in period", "documentation": "The amount of increase through interest accruing in period liabilities arising from financing activities." } } }, "auth_ref": [] }, "bdrx_IncreaseThroughLoansAndBorrowingsLiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IncreaseThroughLoansAndBorrowingsLiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Loans and borrowings classified as non-current 31 December 2024 becoming current in 2025", "documentation": "The amount of increase through loans and borrowings liabilities arising from financing activities." } } }, "auth_ref": [] }, "ifrs-full_IntangibleAssetsAndGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsAndGoodwill", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at end", "verboseLabel": "Net book value" } }, "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "Carrying amount" } }, "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } } }, "auth_ref": [ "r8", "r74" ] }, "ifrs-full_IntangibleAssetsUnderDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IntangibleAssetsUnderDevelopmentMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails2", "http://biodexapharma.com/role/IntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Intangible assets under development [member]" } }, "en": { "role": { "documentation": "This member stands for a class of intangible assets representing such assets under development. [Refer: Intangible assets other than goodwill]" } } }, "auth_ref": [ "r197" ] }, "ifrs-full_InterestCostsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestCostsAbstract", "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Finance expense" } } }, "auth_ref": [] }, "bdrx_InterestExpenseOnDeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "InterestExpenseOnDeferredConsideration", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on deferred consideration" } } }, "auth_ref": [] }, "ifrs-full_InterestExpenseOnLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnLeaseLiabilities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails", "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Interest expense on lease liabilities", "verboseLabel": "Interest expenses" } }, "en": { "role": { "documentation": "The amount of interest expense on lease liabilities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r125" ] }, "ifrs-full_InterestExpenseOnOtherFinancialLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestExpenseOnOtherFinancialLiabilities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Other loans" } }, "en": { "role": { "documentation": "The amount of interest expense on other financial liabilities. [Refer: Interest expense; Other financial liabilities]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_InterestIncomeOnDeposits": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestIncomeOnDeposits", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Interest received on bank deposits" } }, "en": { "role": { "documentation": "The amount of interest income on deposits. [Refer: Interest income]" } } }, "auth_ref": [ "r243" ] }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestPaidClassifiedAsFinancingActivities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest paid", "label": "Interest paid, classified as financing activities" } }, "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } } }, "auth_ref": [ "r87" ] }, "ifrs-full_InterestReceivedClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "InterestReceivedClassifiedAsInvestingActivities", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest received" } }, "en": { "role": { "documentation": "The cash inflow from interest received, classified as investing activities." } } }, "auth_ref": [ "r87" ] }, "bdrx_IssueOfSharesToPurchaseIntangibleAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "IssueOfSharesToPurchaseIntangibleAsset", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Issue of shares to purchase intangible asset" } } }, "auth_ref": [] }, "ifrs-full_IssuedCapital": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "IssuedCapital", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share capital" } }, "en": { "role": { "documentation": "The nominal value of capital issued." } } }, "auth_ref": [ "r188" ] }, "bdrx_LaboratoryEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LaboratoryEquipmentMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Laboratory equipment [member]", "documentation": "The member stands for laboratory equipment." } } }, "auth_ref": [] }, "ifrs-full_LandAndBuildingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LandAndBuildingsMember", "presentation": [ "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Land and buildings [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing land and depreciable buildings and similar structures for use in operations. [Refer: Buildings; Land; Property, plant and equipment]" } } }, "auth_ref": [ "r191" ] }, "bdrx_LapseWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LapseWarrants", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Lapse warrants" } } }, "auth_ref": [] }, "bdrx_Lapsed": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Lapsed", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails1" ], "lang": { "en-us": { "role": { "verboseLabel": "Lapsed", "label": "Lapsed [Default Label]" } } }, "auth_ref": [] }, "ifrs-full_LaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanFiveYearsMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than five years." } } }, "auth_ref": [ "r128", "r129", "r137", "r214", "r215", "r217" ] }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Later than one year and not later than two years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } } }, "auth_ref": [ "r128", "r129", "r137", "r214", "r217", "r243" ] }, "ifrs-full_LaterThanThreeMonthsAndNotLaterThanOneYearMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanThreeMonthsAndNotLaterThanOneYearMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Later than three months and not later than one year [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than three months and not later than one year." } } }, "auth_ref": [ "r213" ] }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanFiveYearsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LaterThanTwoYearsAndNotLaterThanFiveYearsMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Later than two years and not later than five years [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than five years." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_LeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseLiabilities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "At 1 January", "periodEndLabel": "At 31 December", "label": "Lease liabilities" } }, "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } } }, "auth_ref": [ "r123" ] }, "ifrs-full_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements [member]" } }, "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing improvements to assets held under a lease agreement." } } }, "auth_ref": [ "r251" ] }, "ifrs-full_Level3OfFairValueHierarchyMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Level3OfFairValueHierarchyMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]" } }, "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } } }, "auth_ref": [ "r69", "r70", "r113" ] }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyAxis", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r50", "r113" ] }, "ifrs-full_LevelsOfFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LevelsOfFairValueHierarchyDomain", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "auth_ref": [ "r50", "r113" ] }, "ifrs-full_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities [Default Label]" } }, "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } } }, "auth_ref": [ "r15", "r112", "r113", "r115", "r171", "r175" ] }, "ifrs-full_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "auth_ref": [] }, "ifrs-full_LiabilitiesArisingFromFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning", "periodEndLabel": "Ending", "label": "Liabilities arising from financing activities" } }, "en": { "role": { "documentation": "The amount of liabilities for which cash flows were, or future cash flows will be, classified in the statement of cash flows as cash flows from financing activities. [Refer: Cash flows from (used in) financing activities; Liabilities]" } } }, "auth_ref": [ "r204" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesAxis", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Liabilities arising from financing activities [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r204" ] }, "ifrs-full_LiabilitiesArisingFromFinancingActivitiesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiabilitiesArisingFromFinancingActivitiesDomain", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en": { "role": { "documentation": "This member stands for liabilities arising from financing activities. It also represents the standard value for the 'Liabilities arising from financing activities' axis if no other member is used. [Refer: Liabilities arising from financing activities]" } } }, "auth_ref": [ "r204" ] }, "bdrx_LiabilityIncreaseAndDecreaseDescription": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LiabilityIncreaseAndDecreaseDescription", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Liability increase and decrease description" } } }, "auth_ref": [] }, "ifrs-full_LiquidityRiskMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LiquidityRiskMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Liquidity risk [member]" } }, "en": { "role": { "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]" } } }, "auth_ref": [ "r133", "r134", "r135", "r211" ] }, "bdrx_LoanGranted": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LoanGranted", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Loan granted", "label": "LoanGranted" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ifrs-full_LongtermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LongtermBorrowings", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Borrowings", "verboseLabel": "Non current borriwings" } }, "en": { "role": { "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r245" ] }, "ifrs-full_LongtermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "LongtermBorrowingsMember", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Long-term borrowings [member]" } }, "en": { "role": { "documentation": "This member stands for long-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r203", "r206" ] }, "bdrx_LossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LossBeforeTax", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Loss before tax" } } }, "auth_ref": [] }, "bdrx_LossFromOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LossFromOperations", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Loss from operations", "label": "LossFromOperations" } } }, "auth_ref": [] }, "bdrx_LowValueLeasesExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "LowValueLeasesExpensed", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Low value leases expensed", "documentation": "The amount of low value lease expense." } } }, "auth_ref": [] }, "bdrx_MTX228TolimidoneAcquiredIPRDMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "MTX228TolimidoneAcquiredIPRDMember", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "MTX228 tolimidone acquired IPRD* [member]" } } }, "auth_ref": [] }, "bdrx_MTX230ERapaacquiredIPRDMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "MTX230ERapaacquiredIPRDMember", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails", "http://biodexapharma.com/role/IntangibleAssetsDetails1" ], "lang": { "en-us": { "role": { "label": "MTX230 eRapa acquired IPRD* [member]" } } }, "auth_ref": [] }, "ifrs-full_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MajorCustomersAxis", "presentation": [ "http://biodexapharma.com/role/RevenueDetails2" ], "lang": { "en-us": { "role": { "label": "Major customers [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r179" ] }, "ifrs-full_MajorCustomersDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MajorCustomersDomain", "presentation": [ "http://biodexapharma.com/role/RevenueDetails2" ], "lang": { "en": { "role": { "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used." } } }, "auth_ref": [ "r179" ] }, "bdrx_ManagementPersonnalCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ManagementPersonnalCompensation", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails2", "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "Management Personnal Compensation" } } }, "auth_ref": [] }, "ifrs-full_MaturityAnalysisForDerivativeFinancialLiabilities": { "xbrltype": "textBlockItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAnalysisForDerivativeFinancialLiabilities", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentTables" ], "lang": { "en-us": { "role": { "label": "Schedule of derivative financial liability" } }, "en": { "role": { "documentation": "The disclosure of a maturity analysis for derivative financial liabilities, including the remaining contractual maturities for those derivative financial liabilities for which contractual maturities are essential for an understanding of the timing of the cash flows. [Refer: Derivative financial liabilities]" } } }, "auth_ref": [ "r164" ] }, "ifrs-full_MaturityAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityAxis", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Maturity [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r17", "r120", "r128", "r129", "r130", "r131", "r132", "r137", "r154", "r165", "r194", "r214" ] }, "ifrs-full_MaturityDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MaturityDomain", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } } }, "auth_ref": [ "r17", "r120", "r128", "r129", "r130", "r131", "r132", "r137", "r154", "r194", "r214", "r216" ] }, "ifrs-full_MergerReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MergerReserve", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Merger reserve" } }, "en": { "role": { "documentation": "A component of equity that may result in relation to a business combination outside the scope of IFRS 3." } } }, "auth_ref": [ "r245" ] }, "ifrs-full_MergerReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "MergerReserveMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Merger reserve [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity that may result in relation to a business combination outside the scope of IFRS 3." } } }, "auth_ref": [ "r242" ] }, "bdrx_MonteCarloSimulationModelMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "MonteCarloSimulationModelMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Monte Carlo simulation model [member]", "documentation": "The information of monte carlo simulation model." } } }, "auth_ref": [] }, "bdrx_MonteCarloSimulationModelOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "MonteCarloSimulationModelOneMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Monte Carlo simulation model one [member]", "documentation": "The member stands for montec carlos simultaion model." } } }, "auth_ref": [] }, "ifrs-full_NameOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NameOfSubsidiary", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Entity", "verboseLabel": "Name" } }, "en": { "role": { "documentation": "The name of a subsidiary. [Refer: Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r58", "r61", "r98", "r100" ] }, "bdrx_NegativeCashFlowsFromOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NegativeCashFlowsFromOperations", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Negative cash flows from operating activities" } } }, "auth_ref": [] }, "ifrs-full_NetDeferredTaxAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NetDeferredTaxAssets", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredTaxDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Net deferred tax assets" } }, "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r250" ] }, "ifrs-full_NetDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NetDeferredTaxLiabilities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/DeferredTaxDetails" ], "lang": { "en-us": { "role": { "label": "Gross losses" } }, "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } } }, "auth_ref": [ "r250" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "ifrs-full_NoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssets", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Current Assets", "label": "Non-current assets [Default Label]" } }, "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } } }, "auth_ref": [ "r18", "r103", "r207" ] }, "ifrs-full_NoncurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentAssetsAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "auth_ref": [] }, "ifrs-full_NoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "totalLabel": "Total Non-Current Liabilities", "label": "Non-current liabilities [Default Label]" } }, "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } } }, "auth_ref": [ "r19", "r105", "r207" ] }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NoncurrentLiabilitiesAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "auth_ref": [] }, "bdrx_NoncurrentProvisions1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NoncurrentProvisions1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Less: non-current portion" } } }, "auth_ref": [] }, "ifrs-full_NotLaterThanThreeMonthsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotLaterThanThreeMonthsMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Not later than three months [member]" } }, "en": { "role": { "documentation": "This member stands for a time band of not later than three months." } } }, "auth_ref": [ "r243" ] }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NotesAndOtherExplanatoryInformationAbstract", "lang": { "en-us": { "role": { "label": "Notes and other explanatory information [abstract]" } } }, "auth_ref": [] }, "bdrx_NumberOfAdsWarrantsGranted": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NumberOfAdsWarrantsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Number of ADS warrants granted" } } }, "auth_ref": [] }, "ifrs-full_NumberOfOutstandingShareOptions": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfOutstandingShareOptions", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of the year", "periodEndLabel": "Ending of the year", "label": "Number of share options outstanding in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } } }, "auth_ref": [ "r139", "r144", "r147" ] }, "bdrx_NumberOfShareIssuedForConsideration": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NumberOfShareIssuedForConsideration", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, shares", "periodEndLabel": "Ending balance, shares", "documentation": "Number of stock issued for consideration during the period.", "label": "NumberOfShareIssuedForConsideration" } } }, "auth_ref": [] }, "ifrs-full_NumberOfShareOptionsExercisableInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentArrangement", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Options exercisable" } }, "en": { "role": { "documentation": "The number of share options exercisable in a share-based payment arrangement." } } }, "auth_ref": [ "r145" ] }, "ifrs-full_NumberOfShareOptionsExpiredInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsExpiredInSharebasedPaymentArrangement", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Lapsed", "label": "Number of share options expired in share-based payment arrangement" } }, "en": { "role": { "documentation": "The number of share options expired in a share-based payment arrangement." } } }, "auth_ref": [ "r143" ] }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Forfeited" } }, "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } } }, "auth_ref": [ "r141" ] }, "ifrs-full_NumberOfShareOptionsGrantedInSharebasedPaymentArrangement": { "xbrltype": "decimalItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentArrangement", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "label": "Number of options" } }, "en": { "role": { "documentation": "The number of share options granted in a share-based payment arrangement." } } }, "auth_ref": [ "r140" ] }, "ifrs-full_NumberOfSharesAuthorised": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "NumberOfSharesAuthorised", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "label": "Number" } }, "en": { "role": { "documentation": "The number of shares authorised." } } }, "auth_ref": [ "r22" ] }, "bdrx_NumberOfSharesOutstandingGranted": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NumberOfSharesOutstandingGranted", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Granted" } } }, "auth_ref": [] }, "bdrx_NumberOfWarrantsIssued": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "NumberOfWarrantsIssued", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Number of warrants issued" } } }, "auth_ref": [] }, "ifrs-full_OrdinarySharesMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OrdinarySharesMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Ordinary shares [member]" } }, "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments." } } }, "auth_ref": [ "r248" ] }, "ifrs-full_OtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncome", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income net of tax", "label": "Other comprehensive income" } }, "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } } }, "auth_ref": [ "r2", "r27", "r32", "r108" ] }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherComprehensiveIncomeAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other comprehensive income:" } } }, "auth_ref": [] }, "srt_OtherCurrencyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OtherCurrencyMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2" ], "lang": { "en-us": { "role": { "label": "Other Currency [Member]" } } }, "auth_ref": [] }, "ifrs-full_OtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherCurrentPayables", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_CurrentFinancialLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails", "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Other payables" } }, "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r245" ] }, "ifrs-full_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other income" } }, "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r55", "r182", "r183" ] }, "bdrx_OtherInterestReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "OtherInterestReceivable", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails": { "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/FinanceIncomeAndExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Other interest receivable" } } }, "auth_ref": [] }, "bdrx_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "OtherMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "label": "Other [member]", "documentation": "This member stands for information by currency." } } }, "auth_ref": [] }, "ifrs-full_OtherNoncurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherNoncurrentReceivables", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: non-current portion", "label": "Other non-current receivables" } }, "en": { "role": { "documentation": "The amount of non-current other receivables. [Refer: Other receivables]" } } }, "auth_ref": [ "r187" ] }, "ifrs-full_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "OtherReceivables", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Other receivables" } }, "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } } }, "auth_ref": [ "r187" ] }, "bdrx_OtherReceivables1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "OtherReceivables1", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other receivables", "documentation": "The amount represents other receivables.", "label": "OtherReceivables1" } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r233" ] }, "bdrx_OutstandingGrantedOptionsGrantDate": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "OutstandingGrantedOptionsGrantDate", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Grant date", "documentation": "Represent information about the grant date." } } }, "auth_ref": [] }, "ifrs-full_ParValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ParValuePerShare", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share par value (in dollars per share)" } }, "en": { "role": { "documentation": "The nominal value per share." } } }, "auth_ref": [ "r23" ] }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Tax and social security" } }, "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } } }, "auth_ref": [ "r247" ] }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease payments" } }, "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } } }, "auth_ref": [ "r201" ] }, "bdrx_PercentageChangeInFairValue": { "xbrltype": "percentItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PercentageChangeInFairValue", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetails" ], "lang": { "en-us": { "role": { "label": "% change in fair value" } } }, "auth_ref": [] }, "ifrs-full_PercentageOfEntitysRevenue": { "xbrltype": "percentItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PercentageOfEntitysRevenue", "presentation": [ "http://biodexapharma.com/role/RevenueDetails2" ], "lang": { "en-us": { "role": { "label": "Percentage of revenue in excess of 10%" } }, "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } } }, "auth_ref": [ "r268" ] }, "bdrx_PerformanceObligationsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PerformanceObligationsTableTextBlock", "presentation": [ "http://biodexapharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of performance obligations" } } }, "auth_ref": [] }, "bdrx_PharMidaAG1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PharMidaAG1Member", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "PharMida AG 1 [Member]" } } }, "auth_ref": [] }, "bdrx_PharMidaAGMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PharMidaAGMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "PharMida AG [member]", "documentation": "This member stands for entity owned or controlled by another entity." } } }, "auth_ref": [] }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Defined contribution pension cost (note 24)" } }, "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } } }, "auth_ref": [ "r51" ] }, "bdrx_PostemploymentBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PostemploymentBenefits", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails2", "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "Post-employment benefits" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r227" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r229" ] }, "bdrx_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PreFundedWarrantsMember", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails1" ], "lang": { "en-us": { "role": { "label": "Pre-Funded warrants [Member]" } } }, "auth_ref": [] }, "ifrs-full_Prepayments": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Prepayments", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails1", "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Prepayments" } }, "en": { "role": { "documentation": "Receivables that represent amounts paid for goods and services before they have been delivered." } } }, "auth_ref": [ "r187" ] }, "ifrs-full_PrincipalPlaceOfBusinessOfSubsidiary": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PrincipalPlaceOfBusinessOfSubsidiary", "presentation": [ "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Registered office" } }, "en": { "role": { "documentation": "The principal place of business of a subsidiary. [Refer: Principal place of business; Total for all subsidiaries [member]]" } } }, "auth_ref": [ "r59", "r62", "r99", "r101" ] }, "bdrx_PrincipleAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PrincipleAmount", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Principle amount" } } }, "auth_ref": [] }, "bdrx_PrivatePlacements": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PrivatePlacements", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Private Placements" } } }, "auth_ref": [] }, "bdrx_ProceedsFromDisposalOfFixedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromDisposalOfFixedAssets", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from disposal of fixed assets" } } }, "auth_ref": [] }, "bdrx_ProceedsFromEquityLineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromEquityLineOfCredit", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from Equity Line of Credit" } } }, "auth_ref": [] }, "ifrs-full_ProceedsFromExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Exercise of warrants on 22 March 2022" } }, "en": { "role": { "documentation": "The cash inflow from the exercise of share purchase warrants." } } }, "auth_ref": [ "r263" ] }, "ifrs-full_ProceedsFromIssuingShares": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProceedsFromIssuingShares", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails1", "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share issues including warrants, net of costs", "verboseLabel": "Proceeds from issuing shares" } }, "en": { "role": { "documentation": "The cash inflow from issuing shares." } } }, "auth_ref": [ "r200" ] }, "bdrx_ProceedsFromNote": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromNote", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from note" } } }, "auth_ref": [] }, "bdrx_ProceedsFromPrivatePlacement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromPrivatePlacement", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from private placement" } } }, "auth_ref": [] }, "bdrx_ProceedsFromRegisteredOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromRegisteredOffering", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from registered offering" } } }, "auth_ref": [] }, "bdrx_ProceedsFromWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProceedsFromWarrantsExercised", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Proceeds from warrants exercised" } } }, "auth_ref": [] }, "ifrs-full_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent", "weight": 1.0, "order": 1.0 }, "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_AdjustmentsForReconcileProfitLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows", "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Loss for the year attributable to the owners of the parent", "label": "Loss for the year" } }, "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r1", "r26", "r83", "r94", "r96", "r171", "r173", "r207", "r209" ] }, "ifrs-full_ProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAbstract", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Loss used in basic EPS and diluted EPS:" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossAttributableToOrdinaryEquityHoldersOfParentEntityAbstract", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Numerator" } } }, "auth_ref": [] }, "ifrs-full_ProfitLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossBeforeTax", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before tax", "verboseLabel": "Loss before tax", "label": "Profit (loss) before tax" } }, "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r151", "r182", "r183", "r218", "r219" ] }, "ifrs-full_ProfitLossFromContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromContinuingOperations", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Continuing operations", "label": "Profit (loss) from continuing operations" } }, "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations, unless line item indicates otherwise [member]; Profit (loss)]" } } }, "auth_ref": [ "r26", "r107", "r171", "r173" ] }, "ifrs-full_ProfitLossFromOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ProfitLossFromOperatingActivities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Profit (loss) from operating activities" } }, "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } } }, "auth_ref": [ "r195", "r249" ] }, "bdrx_PromissoryNoteIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PromissoryNoteIssued", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Promissory note issued" } } }, "auth_ref": [] }, "bdrx_PromissoryNoteMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PromissoryNoteMember", "presentation": [ "http://biodexapharma.com/role/BorrowingsDetails", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Promissory Note [Member]" } } }, "auth_ref": [] }, "ifrs-full_PropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, plant and equipment", "periodStartLabel": "Balance at beginning", "periodEndLabel": "Balance at ending", "verboseLabel": "Net book value" } }, "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]" } } }, "auth_ref": [ "r7", "r46" ] }, "bdrx_Provision": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Provision", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Opening provision at beginning", "periodEndLabel": "Opening provision at ending", "documentation": "Represnts amount repreesnts provision.", "label": "Provision" } } }, "auth_ref": [] }, "bdrx_ProvisionAgainstFutureLossOnLoanAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProvisionAgainstFutureLossOnLoanAgreement", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails" ], "lang": { "en-us": { "role": { "label": "Provision against future loss on loan agreement" } } }, "auth_ref": [] }, "bdrx_ProvisionsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ProvisionsTextBlock", "presentation": [ "http://biodexapharma.com/role/Provisions" ], "lang": { "en-us": { "role": { "verboseLabel": "Provisions", "label": "ProvisionsTextBlock" } } }, "auth_ref": [] }, "bdrx_PurchaseOfIntangibleAssetdeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "PurchaseOfIntangibleAssetdeferredConsideration", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of intangible asset/deferred consideration", "label": "PurchaseOfIntangibleAssetdeferredConsideration" } } }, "auth_ref": [] }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property, plant and equipment", "label": "Purchase of property, plant and equipment, classified as investing activities" } }, "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } } }, "auth_ref": [ "r199" ] }, "bdrx_QuarterlyPaymentObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "QuarterlyPaymentObligation", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Quarterly payments" } } }, "auth_ref": [] }, "bdrx_RegisteredDirectOffering": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RegisteredDirectOffering", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "December 2025 Registered Offering", "verboseLabel": "Registered Direct Offering" } } }, "auth_ref": [] }, "bdrx_RegisteredOffering": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RegisteredOffering", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Registered Offering" } } }, "auth_ref": [] }, "bdrx_RepaymentproceedsFromPromissoryNote": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RepaymentproceedsFromPromissoryNote", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "(Repayment)/Proceeds from promissory note" } } }, "auth_ref": [] }, "bdrx_RequestedForReimbursement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RequestedForReimbursement", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ContingentLiabilitiesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Requested for reimbursement" } } }, "auth_ref": [] }, "ifrs-full_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "negatedLabel": "Research and development costs", "label": "Research and development expense" } }, "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } } }, "auth_ref": [ "r76" ] }, "bdrx_ResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ResearchAndDevelopmentMember", "presentation": [ "http://biodexapharma.com/role/LossFromOperationsDetails", "http://biodexapharma.com/role/StaffCostsDetails1" ], "lang": { "en-us": { "role": { "label": "Research and development [member]", "documentation": "This member stands for research and development." } } }, "auth_ref": [] }, "bdrx_ReserveForMergerMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ReserveForMergerMember", "presentation": [ "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Merger Reserve [member]", "documentation": "This member stands for merger reserve." } } }, "auth_ref": [] }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "presentation": [ "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } } }, "auth_ref": [ "r52", "r184" ] }, "ifrs-full_RetainedEarnings": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarnings", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit" } }, "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r188", "r189" ] }, "ifrs-full_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsMember", "presentation": [ "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Retained earnings [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } } }, "auth_ref": [ "r5", "r184" ] }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } } }, "auth_ref": [ "r242" ] }, "bdrx_RetirementBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RetirementBenefits", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RetirementBenefitsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Retirement benefits", "label": "RetirementBenefits" } } }, "auth_ref": [] }, "ifrs-full_Revenue": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "Revenue", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome": { "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Revenue" } }, "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } } }, "auth_ref": [ "r29", "r106", "r151", "r169", "r172", "r176", "r177", "r179", "r182", "r183", "r207" ] }, "bdrx_RightOfUseAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "RightOfUseAssetMember", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails3" ], "lang": { "en-us": { "role": { "label": "Right of use asset [member]", "documentation": "The member stands for right of use of assets." } } }, "auth_ref": [] }, "ifrs-full_RightofuseAssets": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RightofuseAssets", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Right of use asset" } }, "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } } }, "auth_ref": [ "r122", "r126" ] }, "ifrs-full_RightofuseAssetsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "RightofuseAssetsMember", "presentation": [ "http://biodexapharma.com/role/PropertyPlantAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Right-of-use assets [member]" } }, "en": { "role": { "documentation": "This member stands for right-of-use assets. [Refer: Right-of-use assets]" } } }, "auth_ref": [ "r121" ] }, "bdrx_SalesRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SalesRevenue", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenue", "label": "SalesRevenue" } } }, "auth_ref": [] }, "bdrx_ScheduleOfCommercialSegmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfCommercialSegmentsTableTextBlock", "presentation": [ "http://biodexapharma.com/role/RevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of commercial segment" } } }, "auth_ref": [] }, "bdrx_ScheduleOfDeferredConsiderationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfDeferredConsiderationTableTextBlock", "presentation": [ "http://biodexapharma.com/role/DeferredConsiderationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of deferred consideration" } } }, "auth_ref": [] }, "bdrx_ScheduleOfFairValueOfWarrantsGrantedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfFairValueOfWarrantsGrantedTableTextBlock", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of fair value of warrants granted" } } }, "auth_ref": [] }, "bdrx_ScheduleOfFapProjectTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfFapProjectTableTextBlock", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of FAP project" } } }, "auth_ref": [] }, "bdrx_ScheduleOfManagementPersonalCompensationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfManagementPersonalCompensationTableTextBlock", "presentation": [ "http://biodexapharma.com/role/StaffCostsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Management Personnel Compensation" } } }, "auth_ref": [] }, "bdrx_ScheduleOfWarrantReserveRecognizedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfWarrantReserveRecognizedTableTextBlock", "presentation": [ "http://biodexapharma.com/role/ShareCapitalTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrant reserve recognize" } } }, "auth_ref": [] }, "bdrx_ScheduleOfWarrantsAccountedForShareBasedPaymentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleOfWarrantsAccountedForShareBasedPaymentsTableTextBlock", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of warrants are accounted for as share based payments" } } }, "auth_ref": [] }, "bdrx_ScheduleofEmolumentsDisclosedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ScheduleofEmolumentsDisclosedTableTextBlock", "presentation": [ "http://biodexapharma.com/role/StaffCostsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of emoluments disclosed" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r221" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r225" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r224" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r230" ] }, "bdrx_SeriesADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesDADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesDADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series D ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesEADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesEADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series E ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesFADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesFADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series F ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesGADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesGADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series G ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesHWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesHWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series H warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesJADSWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesJADSWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "J ADS Warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesKWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesKWarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series K warrants [member]" } } }, "auth_ref": [] }, "bdrx_SeriesLADSwarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SeriesLADSwarrantsMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Series L ADS warrants [Member]" } } }, "auth_ref": [] }, "bdrx_ShareCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ShareCapitalMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Share Capital [Member]" } } }, "auth_ref": [] }, "ifrs-full_SharePremium": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremium", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Share premium" } }, "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r188" ] }, "ifrs-full_SharePremiumMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SharePremiumMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Share premium [member]" } }, "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } } }, "auth_ref": [ "r5" ] }, "bdrx_ShareSubdivisionAndRedesignation": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ShareSubdivisionAndRedesignation", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Share sub-division and re-designation" } } }, "auth_ref": [] }, "bdrx_SharebasedPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharebasedPayment", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails2" ], "lang": { "en-us": { "role": { "label": "Share-based payment" } } }, "auth_ref": [] }, "bdrx_SharesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesExercised", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Exercised" } } }, "auth_ref": [] }, "bdrx_SharesIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued1", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 21 December 2023" } } }, "auth_ref": [] }, "bdrx_SharesIssued2": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued2", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 26 May 2023" } } }, "auth_ref": [] }, "bdrx_SharesIssued3": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued3", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 15 February 2023" } } }, "auth_ref": [] }, "bdrx_SharesIssued4": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued4", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 22 July 2024" } } }, "auth_ref": [] }, "bdrx_SharesIssued5": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued5", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 22 May 2024" } } }, "auth_ref": [] }, "bdrx_SharesIssued6": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued6", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued 19 December 2025" } } }, "auth_ref": [] }, "bdrx_SharesIssued7": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssued7", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued on 15 May 2025" } } }, "auth_ref": [] }, "bdrx_SharesIssuedOnPurchaseIntangibleAsset": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssuedOnPurchaseIntangibleAsset", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Shares issued on purchase Intangible asset" } } }, "auth_ref": [] }, "bdrx_SharesIssuedUnderEloc": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssuedUnderEloc", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Shares issued under ELOC" } } }, "auth_ref": [] }, "bdrx_SharesIssuedUnderElocAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesIssuedUnderElocAgreement", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Shares issued under ELOC agreement" } } }, "auth_ref": [] }, "bdrx_SharesLapsed": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "SharesLapsed", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Lapsed" } } }, "auth_ref": [] }, "bdrx_ShortTermEmployeeBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ShortTermEmployeeBenefits", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails2", "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "Short term employee benefits" } } }, "auth_ref": [] }, "ifrs-full_ShorttermBorrowingsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ShorttermBorrowingsMember", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2" ], "lang": { "en-us": { "role": { "label": "Short-term borrowings [member]" } }, "en": { "role": { "documentation": "This member stands for short-term borrowings. [Refer: Borrowings]" } } }, "auth_ref": [ "r203", "r206" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesAxis", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r60", "r63", "r111" ] }, "ifrs-full_SignificantInvestmentsInSubsidiariesDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SignificantInvestmentsInSubsidiariesDomain", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetails", "http://biodexapharma.com/role/SubsidiariesDetails" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } } }, "auth_ref": [ "r60", "r63", "r111" ] }, "ifrs-full_SocialSecurityContributions": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "SocialSecurityContributions", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Social security contributions and similar taxes" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r254" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r228" ] }, "bdrx_StaffCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "StaffCostsGross", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Staff costs gross", "documentation": "The cost paid to staff gross." } } }, "auth_ref": [] }, "ifrs-full_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityAbstract", "auth_ref": [] }, "ifrs-full_StatementOfChangesInEquityTable": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfChangesInEquityTable", "presentation": [ "http://biodexapharma.com/role/AccountingPoliciesDetailsNarrative", "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1", "http://biodexapharma.com/role/DerivativeFinancialLiabilityCurrentDetailsNarrative", "http://biodexapharma.com/role/ReservesDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails3", "http://biodexapharma.com/role/ShareCapitalDetails", "http://biodexapharma.com/role/ShareCapitalDetails1", "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [table]" } }, "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } } }, "auth_ref": [ "r5" ] }, "ifrs-full_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "auth_ref": [] }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Expenses not deductible for tax purposes" } }, "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } } }, "auth_ref": [ "r35" ] }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TaxExpenseIncomeAtApplicableTaxRate", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Expected tax credit based on the standard rate of United Kingdom corporation tax at the domestic rate of 25% (2024: 25%; 2023: 25.52%)" } }, "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } } }, "auth_ref": [ "r35" ] }, "bdrx_TerminationBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TerminationBenefits", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails2" ], "lang": { "en-us": { "role": { "label": "Termination benefits" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails3" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails3" ], "auth_ref": [] }, "bdrx_Total": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Total", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/LeasesDetails1" ], "lang": { "en-us": { "role": { "label": "Total" } } }, "auth_ref": [] }, "bdrx_TotalCashOutflowForLeases": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TotalCashOutflowForLeases", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/LeasesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Total cash outflow for leases" } } }, "auth_ref": [] }, "bdrx_TotalTaxCreditedToIncomeStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TotalTaxCreditedToIncomeStatement", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/TaxationDetails1" ], "lang": { "en-us": { "role": { "label": "Total tax credited to the income statement" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayables", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Trade and other payables" } }, "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } } }, "auth_ref": [ "r11" ] }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesAbstract", "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Current" } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": "ifrs-full_CurrentFinancialLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails", "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade payables" } }, "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } } }, "auth_ref": [ "r186", "r247" ] }, "ifrs-full_TradeAndOtherCurrentReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherCurrentReceivables", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition", "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade and other receivables", "verboseLabel": "Current portion" } }, "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } } }, "auth_ref": [ "r9", "r20" ] }, "ifrs-full_TradeAndOtherPayables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherPayables", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherPayablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherPayablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total trade and other payables", "label": "Trade and other payables [Default Label]" } }, "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } } }, "auth_ref": [ "r11" ] }, "bdrx_TradeAndOtherPayablesMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TradeAndOtherPayablesMember", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Trade and other payables [member]", "documentation": "This member stands for trade and other payables." } } }, "auth_ref": [] }, "ifrs-full_TradeAndOtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeAndOtherReceivables", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total trade and other receivables", "label": "Trade and other receivables [Default Label]" } }, "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } } }, "auth_ref": [ "r9", "r20" ] }, "ifrs-full_TradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TradeReceivables", "crdr": "debit", "calculation": { "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails": { "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://biodexapharma.com/role/TradeAndOtherReceivablesDetails" ], "lang": { "en-us": { "role": { "label": "Trade receivables" } }, "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } } }, "auth_ref": [ "r187" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "bdrx_TransactionsWithOwnersAbstract": { "xbrltype": "stringItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TransactionsWithOwnersAbstract", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Transactions with owners" } } }, "auth_ref": [] }, "bdrx_TransferToSharePremiumOnExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TransferToSharePremiumOnExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails" ], "lang": { "en-us": { "role": { "label": "Transfer to share premium on exercise of warrants", "documentation": "The amount of transfer to shares premium on excercise of warrants." } } }, "auth_ref": [] }, "bdrx_TransfersInPeriodFromContractAssetsToTradeReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "TransfersInPeriodFromContractAssetsToTradeReceivables", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/RevenueDetails1" ], "lang": { "en-us": { "role": { "label": "Contractual assets, Transfers in the period from contract assets to trade receivables" } } }, "auth_ref": [] }, "ifrs-full_TypesOfRisksAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfRisksAxis", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en-us": { "role": { "label": "Types of risks [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r152", "r157", "r158", "r180" ] }, "ifrs-full_TypesOfRisksDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "TypesOfRisksDomain", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails4" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } } }, "auth_ref": [ "r133", "r134", "r135", "r136", "r152", "r157", "r158", "r180" ] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails2", "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails3" ], "lang": { "en-us": { "role": { "label": "United States of America, Dollars" } } }, "auth_ref": [] }, "ifrs-full_UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "UnusedTaxCreditsForWhichNoDeferredTaxAssetRecognised", "presentation": [ "http://biodexapharma.com/role/DeferredTaxDetails" ], "lang": { "en-us": { "role": { "label": "Potential deferred tax asset" } }, "en": { "role": { "documentation": "The amount of unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax credits [member]]" } } }, "auth_ref": [ "r37" ] }, "bdrx_UnutilisedTaxLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "UnutilisedTaxLosses", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/CriticalAccountingEstimatesAndJudgementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unutilised tax losses" } } }, "auth_ref": [] }, "bdrx_UtilisationOfProvision": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "UtilisationOfProvision", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ProvisionsDetails" ], "lang": { "en-us": { "role": { "label": "Utilisation of provision" } } }, "auth_ref": [] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementAxis", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en-us": { "role": { "label": "Valuation techniques used in fair value measurement [axis]" } }, "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } } }, "auth_ref": [ "r114" ] }, "ifrs-full_ValuationTechniquesUsedInFairValueMeasurementDomain": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "ValuationTechniquesUsedInFairValueMeasurementDomain", "presentation": [ "http://biodexapharma.com/role/FinancialInstruments-RiskManagementDetails1" ], "lang": { "en": { "role": { "documentation": "This member stands for valuation techniques used by the entity to measure fair value. It also represents the standard value for the 'Valuation techniques used in fair value measurement' axis if no other member is used. [Refer: At fair value [member]]" } } }, "auth_ref": [ "r114" ] }, "bdrx_ValueOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ValueOfShares", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total", "label": "ValueOfShares" } } }, "auth_ref": [] }, "bdrx_ValueOfSharesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "ValueOfSharesIssued", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance, amount", "label": "ValueOfSharesIssued" } } }, "auth_ref": [] }, "ifrs-full_WagesAndSalaries": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WagesAndSalaries", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/StaffCostsDetails" ], "lang": { "en-us": { "role": { "label": "Wages and salaries" } }, "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } } }, "auth_ref": [ "r254" ] }, "bdrx_WarrantFiveMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantFiveMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant five [member]" } } }, "auth_ref": [] }, "bdrx_WarrantFourMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantFourMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant four [member]" } } }, "auth_ref": [] }, "bdrx_WarrantInducement": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantInducement", "presentation": [ "http://biodexapharma.com/role/ShareCapitalDetails2" ], "lang": { "en-us": { "role": { "label": "Warrant inducement" } } }, "auth_ref": [] }, "bdrx_WarrantInducementValue": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantInducementValue", "crdr": "credit", "presentation": [ "http://biodexapharma.com/role/FinancialInstrumentsRiskManagementDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant Inducement" } } }, "auth_ref": [] }, "bdrx_WarrantOneMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantOneMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant one [member]" } } }, "auth_ref": [] }, "ifrs-full_WarrantReserve": { "xbrltype": "monetaryItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WarrantReserve", "crdr": "credit", "calculation": { "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition": { "parentTag": "ifrs-full_Equity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfFinancialPosition" ], "lang": { "en-us": { "role": { "label": "Warrant reserve" } }, "en": { "role": { "documentation": "A component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments]" } } }, "auth_ref": [ "r246" ] }, "ifrs-full_WarrantReserveMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WarrantReserveMember", "presentation": [ "http://biodexapharma.com/role/ConsolidatedStatementsOfChangesInEquity", "http://biodexapharma.com/role/ReservesDetails" ], "lang": { "en-us": { "role": { "label": "Warrant reserve [member]" } }, "en": { "role": { "documentation": "This member stands for a component of equity resulting from issuing share purchase warrants, other than those resulting from share-based payment arrangements. [Refer: Reserve of share-based payments [member]]" } } }, "auth_ref": [ "r242" ] }, "bdrx_WarrantSevenMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantSevenMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant Seven [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantSixMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantSixMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant seven [member]" } } }, "auth_ref": [] }, "bdrx_WarrantThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantThreeMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant three [member]" } } }, "auth_ref": [] }, "bdrx_WarrantTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantTwoMember", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "label": "Warrant two [member]" } } }, "auth_ref": [] }, "bdrx_Warrants": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "Warrants", "presentation": [ "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails1" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares outstanding at beginning", "periodEndLabel": "Number of shares outstanding at end", "label": "Warrants" } } }, "auth_ref": [] }, "bdrx_WarrantsExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsExercisable", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants exercisable" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant1Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant1Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 1 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant2Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant2Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 2 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant3Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant3Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 3 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant4Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant4Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 4 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant5Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant5Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 5 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsGrant6Member": { "xbrltype": "domainItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsGrant6Member", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Warrants Grant 6 [Member]" } } }, "auth_ref": [] }, "bdrx_WarrantsIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WarrantsIssued", "crdr": "debit", "presentation": [ "http://biodexapharma.com/role/CashAndCashEquivalentsAndCashFlowSupportingNotesDetails2", "http://biodexapharma.com/role/DerivativeFinancialLiability-CurrentDetails" ], "lang": { "en-us": { "role": { "label": "Warrants issued", "documentation": "The amount represent of warrants issued." } } }, "auth_ref": [] }, "ifrs-full_WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WarrantsMember", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails2", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Warrants [member]" } }, "en": { "role": { "documentation": "This member stands for warrants." } } }, "auth_ref": [ "r255" ] }, "bdrx_WeightedAverageExercisePriceOfOptionsExercised": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageExercisePriceOfOptionsExercised", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of options exercised" } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "xbrltype": "perShareItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Exercise Price" } }, "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } } }, "auth_ref": [ "r142" ] }, "bdrx_WeightedAverageExercisePriceOfShareOptionsForfeited": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsForfeited", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of options forfeited", "documentation": "It represents as a weighted average exercise price of share options forfeIted." } } }, "auth_ref": [] }, "bdrx_WeightedAverageExercisePriceOfShareOptionsGranted": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsGranted", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of options granted", "documentation": "It represents as a weighted average exercise price of share options granted." } } }, "auth_ref": [] }, "bdrx_WeightedAverageExercisePriceOfShareOptionsLapsed": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsLapsed", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of options lapsed" } } }, "auth_ref": [] }, "bdrx_WeightedAverageExercisePriceOfShareOptionsOutstanding": { "xbrltype": "perShareItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageExercisePriceOfShareOptionsOutstanding", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average exercise price of outstanding options", "documentation": "It represents as a weighted average exercise price of share options outstanding." } } }, "auth_ref": [] }, "bdrx_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions1": { "xbrltype": "durationItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions1", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails", "http://biodexapharma.com/role/Share-basedPaymentsDetails2" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life of outstanding options", "documentation": "The weighted average remaining contractual life of outstanding share options." } } }, "auth_ref": [] }, "bdrx_WeightedAverageSharePriceShareOptionsGranted1": { "xbrltype": "decimalItemType", "nsuri": "http://biodexapharma.com/20251231", "localname": "WeightedAverageSharePriceShareOptionsGranted1", "presentation": [ "http://biodexapharma.com/role/Share-basedPaymentsDetails1", "http://biodexapharma.com/role/Share-basedPaymentsDetails3" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "The weighted average share price used as input to the option pricing model to calculate the fair value of share options granted." } } }, "auth_ref": [] }, "ifrs-full_WeightedAverageShares": { "xbrltype": "sharesItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageShares", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average number of ordinary shares used in basic EPS:" } }, "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } } }, "auth_ref": [ "r66" ] }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "xbrltype": "stringItemType", "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full", "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "presentation": [ "http://biodexapharma.com/role/LossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Denominator" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://biodexapharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r239" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2024-03-27" }, "r1": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2024-03-27" }, "r2": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r3": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r4": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2024-03-27" }, "r5": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard", "URIDate": "2024-03-27" }, "r6": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "138", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_138_b&doctype=Standard", "URIDate": "2024-03-27" }, "r7": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2024-03-27" }, "r8": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2024-03-27" }, "r9": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2024-03-27" }, "r10": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2024-03-27" }, "r11": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2024-03-27" }, "r12": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2024-03-27" }, "r13": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2024-03-27" }, "r14": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2024-03-27" }, "r15": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r16": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard", "URIDate": "2024-03-27" }, "r17": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard", "URIDate": "2024-03-27" }, "r18": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r19": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard", "URIDate": "2024-03-27" }, "r20": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2024-03-27" }, "r21": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r22": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r23": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r24": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r25": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_b&doctype=Standard", "URIDate": "2024-03-27" }, "r26": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2024-03-27" }, "r27": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2024-03-27" }, "r28": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "81B", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2024-03-27" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2024-03-27" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2024-03-27" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2024-03-27" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard", "URIDate": "2024-03-27" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard", "URIDate": "2024-03-27" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2024-03-27" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "c", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2024-03-27" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2024-03-27" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2024-03-27" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2024-03-27" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2024-03-27" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_i&doctype=Standard", "URIDate": "2024-03-27" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73&doctype=Standard", "URIDate": "2024-03-27" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "75", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_a&doctype=Standard", "URIDate": "2024-03-27" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2024-03-27" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard", "URIDate": "2024-03-27" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2024-03-27" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard", "URIDate": "2024-03-27" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "24", "IssueDate": "2024-01-01", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2024-03-27" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "26", "IssueDate": "2024-01-01", "Paragraph": "35", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2024-03-27" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2024-03-27" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "27", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2024-03-27" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard", "URIDate": "2024-03-27" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard", "URIDate": "2024-03-27" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2024-03-27" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "130", "Subparagraph": "d", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "130", "Subparagraph": "f", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard", "URIDate": "2024-03-27" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "134", "Subparagraph": "e", "Clause": "iiA", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard", "URIDate": "2024-03-27" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "37", "IssueDate": "2024-01-01", "Paragraph": "86", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_86&doctype=Standard", "URIDate": "2024-03-27" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2024-03-27" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2024-03-27" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard", "URIDate": "2024-03-27" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_76&doctype=Standard", "URIDate": "2024-03-27" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2024-03-27" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard", "URIDate": "2024-03-27" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2024-03-27" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard", "URIDate": "2024-03-27" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard", "URIDate": "2024-03-27" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_a&doctype=Standard", "URIDate": "2024-03-27" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44B_c&doctype=Standard", "URIDate": "2024-03-27" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2024-03-27" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2024-03-27" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2024-03-27" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "32", "Subparagraph": "a", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "10", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_10_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "12", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_a&doctype=Standard", "URIDate": "2024-03-27" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_12_b&doctype=Standard", "URIDate": "2024-03-27" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "19B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_a&doctype=Standard", "URIDate": "2024-03-27" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "19B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_19B_b&doctype=Standard", "URIDate": "2024-03-27" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B12", "Subparagraph": "b", "Clause": "viii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B4", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2024-03-27" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2024-03-27" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard", "URIDate": "2024-03-27" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2024-03-27" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "13", "IssueDate": "2024-01-01", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard", "URIDate": "2024-03-27" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard", "URIDate": "2024-03-27" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard", "URIDate": "2024-03-27" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2024-03-27" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "120", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2024-03-27" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_a&doctype=Standard", "URIDate": "2024-03-27" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_b&doctype=Standard", "URIDate": "2024-03-27" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2024-03-27" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_53&doctype=Standard", "URIDate": "2024-03-27" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard", "URIDate": "2024-03-27" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard", "URIDate": "2024-03-27" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard", "URIDate": "2024-03-27" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2024-03-27" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard", "URIDate": "2024-03-27" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard", "URIDate": "2024-03-27" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard", "URIDate": "2024-03-27" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard", "URIDate": "2024-03-27" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2024-03-27" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2024-03-27" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard", "URIDate": "2024-03-27" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2024-03-27" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "iv", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2024-03-27" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "v", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_v&doctype=Standard", "URIDate": "2024-03-27" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vi", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2024-03-27" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "Clause": "vii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b_vii&doctype=Standard", "URIDate": "2024-03-27" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_b&doctype=Standard", "URIDate": "2024-03-27" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2024-03-27" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2024-03-27" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "2", "IssueDate": "2024-01-01", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2024-03-27" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "3", "IssueDate": "2024-01-01", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2024-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "5", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "b", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2024-03-27" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2024-03-27" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "22A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_22A&doctype=Standard", "URIDate": "2024-03-27" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2024-03-27" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard", "URIDate": "2024-03-27" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard", "URIDate": "2024-03-27" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2024-03-27" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2024-03-27" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2024-03-27" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2024-03-27" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard", "URIDate": "2024-03-27" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2024-03-27" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2024-03-27" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard", "URIDate": "2024-03-27" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "8", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard", "URIDate": "2024-03-27" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2024-03-27" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2024-03-27" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2024-03-27" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2024-03-27" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2024-03-27" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2024-03-27" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard", "URIDate": "2024-03-27" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2024-03-27" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard", "URIDate": "2024-03-27" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Effective 2025-01-01", "Name": "IAS", "Number": "21", "IssueDate": "2024-01-01", "Paragraph": "A19", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard", "URIDate": "2024-03-27" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Note": "Expired 2023-01-01", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_22&doctype=Standard", "URIDate": "2024-03-27" }, "r182": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard", "URIDate": "2024-03-27" }, "r183": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard", "URIDate": "2024-03-27" }, "r184": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r185": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard", "URIDate": "2024-03-27" }, "r186": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard", "URIDate": "2024-03-27" }, "r187": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2024-03-27" }, "r188": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r189": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r190": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "80", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_80_c&doctype=Standard", "URIDate": "2024-03-27" }, "r191": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_b&doctype=Standard", "URIDate": "2024-03-27" }, "r192": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2024-03-27" }, "r193": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2024-03-27" }, "r194": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2024-03-27" }, "r195": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "32", "IssueDate": "2024-01-01", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2024-03-27" }, "r196": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "36", "IssueDate": "2024-01-01", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard", "URIDate": "2024-03-27" }, "r197": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "119", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_119_g&doctype=Standard", "URIDate": "2024-03-27" }, "r198": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2024-03-27" }, "r199": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2024-03-27" }, "r200": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2024-03-27" }, "r201": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2024-03-27" }, "r202": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r203": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44C&doctype=Standard", "URIDate": "2024-03-27" }, "r204": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "44D", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44D&doctype=Standard", "URIDate": "2024-03-27" }, "r205": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI", "URIDate": "2024-03-27" }, "r206": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Section": "C Reconciliation of liabilities arising from financing activities", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_C_TI", "URIDate": "2024-03-27" }, "r207": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r208": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "15", "IssueDate": "2024-01-01", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r209": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2024-03-27" }, "r210": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "17", "IssueDate": "2024-01-01", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2024-03-27" }, "r211": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard", "URIDate": "2024-03-27" }, "r212": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2024-03-27" }, "r213": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_c&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r214": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r215": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r216": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2024-03-27" }, "r217": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2024-03-27" }, "r218": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard", "URIDate": "2024-03-27" }, "r219": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2024-03-27" }, "r220": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r221": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r222": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r223": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r224": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r226": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r227": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r228": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r229": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r230": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r231": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r232": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r233": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r234": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r235": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r237": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r238": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r239": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r240": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r241": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2024-03-27" }, "r242": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard", "URIDate": "2024-03-27" }, "r243": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2024-03-27" }, "r244": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_117&doctype=Standard", "URIDate": "2024-03-27" }, "r245": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard", "URIDate": "2024-03-27" }, "r246": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2024-03-27" }, "r247": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard", "URIDate": "2024-03-27" }, "r248": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2024-03-27" }, "r249": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "1", "IssueDate": "2024-01-01", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard", "URIDate": "2024-03-27" }, "r250": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "12", "IssueDate": "2024-01-01", "Paragraph": "81", "Subparagraph": "g", "Clause": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2024-03-27" }, "r251": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_37&doctype=Standard", "URIDate": "2024-03-27" }, "r252": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2024-03-27" }, "r253": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "16", "IssueDate": "2024-01-01", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2024-03-27" }, "r254": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "19", "IssueDate": "2024-01-01", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_9&doctype=Standard", "URIDate": "2024-03-27" }, "r255": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "33", "IssueDate": "2024-01-01", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2024-03-27" }, "r256": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2024-03-27" }, "r257": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "Clause": "ii", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2024-03-27" }, "r258": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2024-03-27" }, "r259": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "38", "IssueDate": "2024-01-01", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_118&doctype=Standard", "URIDate": "2024-03-27" }, "r260": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "40", "IssueDate": "2024-01-01", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2024-03-27" }, "r261": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard", "URIDate": "2024-03-27" }, "r262": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "41", "IssueDate": "2024-01-01", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2024-03-27" }, "r263": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard", "URIDate": "2024-03-27" }, "r264": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2024-03-27" }, "r265": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2024-03-27" }, "r266": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard", "URIDate": "2024-03-27" }, "r267": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IAS", "Number": "7", "IssueDate": "2024-01-01", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard", "URIDate": "2024-03-27" }, "r268": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "IFRS", "Number": "8", "IssueDate": "2024-01-01", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard", "URIDate": "2024-03-27" } } }